Composition comprising avenanthramide or analog thereof having improved stability

Abstract

To provide compositions comprising avenanthramides or analogs thereof having improved stability during storage while stabilization does not lead to discoloration.SOLUTION: Disclosed is a composition comprising an avenanthramide and a stabilizer, where (a1) the avenanthramide is avenanthramide C; and (a2) the stabilizer is selected from the group consisting of EDTA or a salt thereof, ascorbic acid, citric acid, lactic acid, 4-hydroxyacetophenone, malic acid, tartaric acid, tetrasodium glutamate diacetate, trisodium ethylenediamine disuccinate, phytic acid, 6-paradol and a mixture thereof.SELECTED DRAWING: None

Description

[Technical field]

[0001] The present invention generally comprises at least one avenanthramide or an analog or modified form thereof. The present invention includes an oat extract containing avenanthramide or its analogues having improved stability. or compositions comprising same; their cosmetic or medical uses; food, nutritional supplements Use of such compositions for preparing dietary supplements, cosmetic, pharmaceutical or veterinary preparations; and to food, dietary supplement, cosmetic, pharmaceutical or veterinary preparations containing such compositions. Finally, the present invention relates to a stabilization method for avenantramide. Concerning specific stabilizers for [Background technology]

[0002] Poaceae is also known as Gramineae, a family of grasses. The grasses are a large and nearly ubiquitous family of monocotyledonous flowering plants. Grasses are an economically important family of plants that have been used as livestock feed for 6,000 years. It is cultivated in the United States and is the grain of grasses, e.g. wheat, rice, corn (corn Crop, barley, sorghum, millet and oats remain the most important food crops for humans. It is an object.

[0003] Cereal grains are unique in that they contain many biologically active compounds. , e.g., edible fiber (arabinoxylan, β-glucan, cellulose, lignin and gnans), sterols, tocopherols, tocotrienols, phenolic compounds, vitamins It is an excellent source of minerals and trace elements.

[0004] Oatmeal has been shown to act as a soothing agent to relieve the itching and irritation associated with various dry skin conditions. It has been in use for centuries. Medical texts describe automyelitis for a variety of skin conditions. The study promoted topical application of colloidal oatmeal in dermatological practice. The most common clinical applications are in the treatment of pruritic skin conditions, e.g., atopic dermatitis and allergies. The clinical application of oats is as an adjunctive therapy for sensitive or irritant contact dermatitis. The potential anti-irritant activity of oat extract has been established both in vitro and in clinical studies. The release of arachidonic acid from phospholipids in keratinocytes was stimulated by ionophore stimulation. It has been shown to reduce inflammatory bowel disease and inhibit prostaglandin biosynthesis. Despite its widespread use, phytochemicals present in oats mediate anti-inflammatory activity. Few studies have investigated the substance.

[0005] Oats are made up of two main species, Avena sativa L. and Avena nu da L. (synonym Avena sativa by Gillet and Magne) subsp. nuda (L.), and Avena sativa v by Koern A. sativa is found in oats or hulled plants. Also known as oat, it grows in cool temperate climates, especially in the cold, humid climates of northern Europe and North America. A. nuda is mainly cultivated in areas where the husk is removed when the crop is collected. It has a husk-free threshing property similar to that of wheat, so it is called naked oats or hulled oats. Hulled oats account for the majority of oat production globally. representative, except in China, where naked oat is the most common species.

[0006] The composition of oats is mainly starch (65-85%), protein (15-20%), enzymes Approximately 2-8.5% of the diet contains fats (3-11%) and a high content of β-glucan. Oats also contain other important bioactive compounds, e.g., phenolic compounds. Contains:

[0007] The general definition of a phenolic compound is a phenolic compound that contains one or more hydroxyl groups. Any compound that contains a benzene ring. Phenolic acids, flavonoids, condensed tannins Examples are benzoquinones, coumarins and alkylresorcinols. In cereals, these compounds Located mainly in the pericarp, it can be concentrated by peeling the kernel to produce the bran Phenolic compounds are flavonoids (flavonols, flavones, isoflavones, amines, etc.). Flavonoids are classified into three groups: flavonoids, flavanols, flavanones, etc. Phenolic compounds can be grouped into free phenols or glycosidic forms. Phenolic compounds tend to be relatively polar and are usually found in pure form. or in aqueous alcohols, such as ethanol and methanol, or in aqueous acetone Many phenolic compounds in cereals (e.g., phenolic acids and flavonoids) Some phenols have also been reported in fruits and plants, but only a few are found in one plant species. For example, oat avenanthramide is unique. Phenolic compounds have many activities. It has been shown that it has anti-inflammatory properties, but most importantly, it inhibits the immune system mediated by harmful free radicals. The antioxidant activity of phytosterols prevents lipid peroxidation and oxidative damage to cells. - radicals and donate hydrogen atoms or electrons, or chelated metal cations. This is related to the ability of phenolic compounds to World, 2007, pp. 105-111]. Phenolic compounds have antioxidant properties. Therefore, reactive oxygen species (i.e. superoxide anion, hydroxyl radicals and and peroxy radicals) (e.g., heart disease and cancer) can.

[0008] The types and concentrations of phenolic compounds in whole wheat grains depend on the plant diversity and properties of the grain. High levels of phenolic acids, tocopherols and alkyl (alkane) acids In addition to containing (nyl)resorcinol derivatives, oats are especially rich in avenanthramides. (Avns; N-cinnamoyl anthranilate alkaloids or anthranilic acid amines) These compounds are found in cereal grains and are known as oleic acid compounds. is an antipathogenic agent, produced by plants in response to exposure to pathogens, e.g., fungi. .

[0009] Avenanthramides (hereafter referred to as Avns or a single avenanthramide compound) Avn is a compound that is a mixture of anthranilic acid and hydroxycinnamic acid with an amide bond. It is a low molecular weight phenolic amide containing an acid moiety, and is found in both A. sativa and A. nud a is also a group of naturally occurring phenolic amides in oats. First identified as a phytoalexin produced by plants in response to exposure to pathogens Oats contain a unique group of approximately 40 different types of Avns, which It is present in both grains and leaves. The most abundant is Avn A (N-(4'-hydroxycinnamate). namoyl)-5-hydroxyanthranilic acid), Avn B (N-(4'-hydroxy- 3'-Methoxycinnamoyl)-5-hydroxyanthranilic acid) and Avn C(N -(3'-4'-dihydroxycinnamoyl)-5-hydroxyanthranilic acid) These are amides of 5-hydroxyanthranilic acid, and include p-coumarin, ferulic acid, and These Avns are constitutively expressed in seeds and nuts. They appear in almost all milled fractions, but their highest concentrations are in the bran and seeds. It occurs in the outer layer of the fruit [Boz H, Czech Journal of Food Sciences, 2015, Vol. 33(No. 5): pp. 399-404. The total content of avenanthramides (Avns) in rice varies from about 2 to 100 mg / kg depending on the variety and agronomic treatment. 700 mg / kg (0.0002-0.07%) [Maliaro va M et al., Journal of the Brazilian Chemical Society, 2015, Volume 26(No. 11), Pages 2369-2378].

[0010] The extraction of Avns from oats can be performed using various solvent compositions, e.g., pure or diluted Ethanol and methanol were used. The extraction procedure is carried out using, for example, naked oat, 50% aqueous ethanol, etc. under controlled heating. [Tong L et al., Journal of Integrative Agr iculture, 2014, vol. 13, p. 1809].

[0011] Maliarova, M. et al., Journal of the Brazilian Chemical Society, 2015, Vol. 26(11), 2369-2378 Page, Methanol, Ethanol, and the Extraction of Avns from Naked Oat Bran The efficiency of isopropanol and ethanol was compared. The optimum conditions for the highest yield of Avns were The extraction temperature was 55°C and the extraction time was 165 min.

[0012] Avenanthramide has excellent antioxidant activity both in vitro and in vivo. and cellular oxidative dysfunction and oxidative stress-related diseases, such as neurodegeneration and cardiovascular disease. Anti-inflammatory, anti-irritant, anti-atherogenic and anti-proliferative properties that may prevent or limit the development of vascular disease. Has reproductive activity and provides additional protection against skin irritation, aging, CHD and cancer Several studies have demonstrated that the application of avenanthramides in therapeutic agents is The number of cases is increasing [Perrelli A et al., Oxidative Medicine a nd Cellular Longevity, 2018, DOI:10.1155 / 2 018 / 6015351].

[0013] The antioxidant activity of Avns was similar to that of typical cereal constituents ferulic acid, gentisic acid, and p-hydroxybutyric acid. Protocatechuic acid, silyloxybenzoic acid The antioxidant activity of these compounds was found to be 10 to 30 times higher than that of vanillin, vanillic acid, and valinic acid. Avns differ in antioxidant activity, with Avn C having the highest activity, followed by Avn B and A. This is followed by vn A. Oat extracts rich in Avns showed LD Oat antioxidants lower serum cholesterol and inhibit LDL oxidation. Inhibits terol oxidation and peroxidation, potentially reducing cardiovascular risk This has been confirmed in animal studies and in human clinical trials. Consumption of these foods, not only due to their high fiber content, but also due to Avns, is associated with increased risk of colon cancer. Another study showed that Avns-rich oat extracts can reduce The compound has been shown to inhibit atherosclerosis and activation of the NF-kB transcription factor. NF-kB transcription factors are regulators of infection and inflammation [Hueseyin B oz, Phenolic Amides (Avenanthramides) in Oa ts-A Review, Czech J.Food Sci., Vol. 33, 2015(5 No., pp. 399-404.

[0014] WO2004 / 047833A1 describes a method for the study of substance P-induced release of histamine from mast cells. The inhibition and treatment and prevention of itch with substances of formula 2 above are described.

[0015] WO2017 / 159964A1 describes an active compound for preventing or treating hearing loss. Compositions are described that include avenanthramide or its derivatives as an ingredient.

[0016] EP0157420A2 discloses avenanthramide L as a 5-lipoxygenase inhibitor. The present invention describes avenanthramides, which include compounds that are structurally related to

[0017] Lotts T et al., Experimental Dermatology, 2017, Volume 26 (No. 8): Pages 739-742 describes dihydroavenanthramide D (CAS 697 235-49-7, INCI name: Hydroxyphenylpropamidobenzoic acid; Symris How does SymCalmin®, the active ingredient provided by SymCalmin.co.jp, help treat obesity? Inhibits cellular degranulation and exerts anti-inflammatory effects through interaction with the neurokinin-1 receptor It also describes how this is done.

[0018] Cereal phenolic compounds, especially avenanthramides, have potent beneficial biological activities, This makes avenanthramide suitable for oral administration and / or administration to humans and animals. Valuable and highly interesting for nutritional, cosmetic and health uses for topical application It is a tasty, natural active ingredient.

[0019] Therefore, they are stable and do not decompose during processing steps, storage or transportation, as well as being resistant to light and and stable to the effects of UV radiation, metal cations, air, or certain enzymes. based on naturally occurring, well tolerated, biodegradable substances, especially skin of novel formulations for use in the protection and prevention and / or treatment of skin diseases The ongoing need and development of new technologies in the food, cosmetics, pharmaceutical and veterinary industries Consumer demand is there.

[0020] Oxidative degradation and autoxidation processes play a crucial role in the stability of the preparation. Because they can destroy the desired components, Its absence would result in unpleasant or undesirable decomposition products or would adversely affect the properties of the products, such as color. may adversely affect the physical performance characteristics and therefore often the value of the product. This is because it reduces

[0021] Avenanthramides find applications in the nutritional, cosmetic, pharmaceutical or veterinary industries. However, due to their chemical structure, these are unstable compounds. Antioxidant activity is related to the number and position of hydroxyl groups in the molecule. The antioxidant efficiency of is strongly enhanced by the introduction of a second hydroxyl group at the ortho or para position. to give one or two methoxy substituents ortho to the hydroxyl group. Therefore, avenanthramide compounds reduce the oxidation of other compounds. By reducing or inhibiting the oxidation of other compounds, Avena The nitramide compounds themselves are subject to oxidation, i.e., decomposition over time. This means that avenanthramide is no longer present as an active substance or ingredient or or may be present in trace concentrations that are detrimental to the composition or final product. do.

[0022] Among the avenanthramide compounds, avenanthramide C in particular is known to have low stability. This leads to rapid instability during storage.

[0023] Therefore, in order to maintain the activity of avenanthramide as an active substance or active ingredient, and to extend the shelf life of compositions or preparations containing avenanthramide compounds. In this case, the composition or preparation is to be stabilized.

[0024] Stabilizing compositions containing one or a mixture of avenanthramides Vitamin C (ascorbic acid) is still used to this day for this purpose. The use of Vitamin C (ascorbic acid) in large amounts results in an unpleasant discoloration of the composition, and therefore Especially in final formulations such as emulsions, vitamin C (ascorbic acid) reduces the Stabilization by avenanthramides results in undesirable discoloration. The use of chloramide stabilizers is not yet known.

[0025] Therefore, it is difficult to achieve therapeutic concentrations or bioavailability of the avenanthramide substances. It is extremely difficult to achieve this. Summary of the Invention [Problem to be solved by the invention]

[0026] Thus, an object of the present invention is to provide a composition that exhibits enhanced stability during storage while preventing discoloration. A composition comprising avenanthramide or an analog thereof or an avenanthramide-containing composition, The present invention provides an oat extract containing oat mido or an analog thereof.

[0027] In particular, the goal of the present invention is to stabilize avenanthramides in compositions or in oat extracts. Thus, the beneficial biological activity and pharmaceutical properties of avenanthramides themselves can be Natural, biodegradable, cosmetically or pharma- ceutically acceptable, safe, The aim of the present invention is to propose a stabilizer substance which is easy to use and stable. The present invention relates to avenanthramide compounds, particularly avenanthramides, in compositions or oat extracts. A, B, C or L or avenanthramide analogue compound dihydroavenanthramide D ( 2-{[3-(4-hydroxyphenyl)propanoyl]amino}benzoic acid; INCI name : Hydroxyphenylpropamidobenzoic acid; CAS 697235-49-7) to stabilize natural, biodegradable, cosmetically or pharma- ceutically acceptable, non-discoloring To propose a stabilizer substance that is acceptable for the application, safe, easy to use, and stable. It is.

[0028] Surprisingly, avenanthramide, especially avenanthramide Avenanthramide C, the most unstable of the three, is highly unstable, especially at low concentrations, and is highly susceptible to the addition of stabilizers, especially chiral amides. At least one stabilizer which is a stabilizing agent or an organic acid or an antioxidant or a mixture thereof As a result, it has been found that the cellulose can be significantly stabilized by some of the above mentioned stabilizer combinations. A synergistic effect can even be demonstrated against at least one Avena species. Avenanthramide analogue is dihydroavenanthramide D (2-{[3-(4-hydroxyphenyl This is the case when the compound is a benzoic acid (amino)-(phenyl)propanoyl)aminobenzoic acid. [Means for solving the problem]

[0029] The above object is achieved according to a first aspect of the present invention, (i) at least one avenanthramide or analog thereof, or at least one Oats containing evananthramide or its analogues Extracts, as well as (ii) a compound selected from the group consisting of chelating agents, organic acids, antioxidants, and mixtures thereof; At least one stabilizer This is achieved by providing a composition comprising or consisting of: In a second aspect, the present invention relates to the use of said composition as a cosmetic product, in particular for skin protection and skin care. In skin care, scalp protection and care, hair care, nail care, or for skin conditions, Intolerable and sensitive skin, skin irritation, skin redness, wheals, pruritus (itching), skin aging, Wrinkles, loss of skin volume, loss of skin elasticity, pigmentation spots, pigmentation abnormalities, or dry skin, i.e. Dermatological cosmetics in the prevention and / or treatment of dry skin that requires skin moisturization Regarding use as a

[0030] In a third aspect, the present invention relates to a method for treating, in particular, a skin or keratinopathy, in particular a barrier-associated inflammation. have pathogenic, immunoallergic, atherogenic, dry or hyperproliferative components in the prevention and / or treatment of skin or keratinopathy resulting in ROS generation in the prevention and / or treatment of skin diseases associated with an increase in Serum LDL cholesterol in the prevention and / or treatment of allergic reactions and coronary heart disease To reduce sterol and lipid levels, to reduce blood pressure, to increase insulin Medicinal products for use in improving insulin sensitivity and enabling control of blood glucose levels The present invention relates to the use of said composition as a

[0031] In a fourth aspect, the present invention provides food, dietary supplement, cosmetic, pharmaceutical and veterinary preparations. The present invention relates to the use of said composition for the preparation of a

[0032] In a fifth aspect, the present invention provides a food, dietary supplement or cosmetic product comprising a composition according to the present invention. , and for pharmaceutical and veterinary preparations.

[0033] Finally, the present invention provides a method for the stabilization of avenanthramide or analog avenanthramide compounds. The present invention relates to the use of one or more of said stabilizers for the preparation of a pharmaceutical composition comprising:

[0034] The present invention is set forth in the appended claims. The present invention and preferred modifications thereof, further objects and advantages are also set forth in the following detailed description taken in conjunction with the accompanying examples. This is also clear from the explanation. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0035] In a first aspect, the present invention provides a method for producing a composition comprising the steps of: - at least one avenanthramide or its analogue, or at least one avenanthramide an oat extract containing venanthramide or an analog thereof; and At least one selected from the group consisting of chelating agents, organic acids, antioxidants and mixtures thereof. At least one stabilizer The present invention relates to a composition comprising or consisting of:

[0036] The first major component of the composition according to the first aspect of the present invention is at least one avenanthrene. or at least one avenanthramide or analog thereof It is an oat extract comprising:

[0037] The phrase "at least one" when used in this document means, for example, It may contain any one of the avenanthramides or more than one avenanthramide. In addition, the phrase "at least one" refers to a composition or oat extract comprising When applied to a list, it means any one combination of the items specified in the list. do.

[0038] The composition according to the first aspect of the invention comprises the specified components described in more detail below. It is prepared by combining the following:

[0039] In the context of the present invention, the term "avenanthramide" (anthranilic acid amide) means Members of the group of phenolic alkaloids, i.e. mainly from oats (Avena sativa) iva), but as described in detail hereinafter On the eggs of the butterflies (Pieris brassicae and P. rapae) and fungi Infected carnations (Dianthus caryophyllus) also have Naturally occurring avenanthramides, or those described in detail hereinafter, This is believed to mean non-naturally occurring, artificially produced avenanthramide analogues such as do.

[0040] The avenanthramides of the compositions of the present invention are found in nature and are isolated and purified from oats. The two main species of oat are Avena sativa L. and Avena nuda L. (synonyms according to Gillet and Magne Avena sativa subsp. nuda (L.) and Avena by Koern A. sativa var. nuda (L.) is one example. Also known as oats or hulled oats. A. nuda is a plant that grows in the husks of the harvested oats. The hulled oats are removed when the oats are cooked, and are therefore known as naked or dehulled oats. Oats can be processed to separate them into constituent fractions, including oat kernels; Avenanthramides appear to be most highly concentrated in peripheral regions, husks, trichomes, or straw. More than 50 distinct avenanthramides have been isolated from oat kernels. [Collins, Journal of Agricultural and Food Chemistry, vol. 37 (1989), pp. 60-66].

[0041] Avns can be represented by the following general formula 1: [ka]

[0042] Table 1 below shows examples of naturally occurring Avns based on general formula 1.

[0043] [Table 1]

[0044] Several studies have demonstrated that these natural products have anti-inflammatory, antioxidant, anti-itch, anti-irritant and anti- It has been demonstrated to have atherogenic activity.

[0045] Naturally occurring avenanthramides or mixtures of avenanthramides as described above The invention relates to an extract from a plant of the genus Avena, in particular any oat species, fresh or dried. or parts thereof, for example Avena sativa or Avena nudum Obtained from crushed or uncrushed kernels, husks, trichomes or oat straw of the a species It is possible to obtain, enrich, and isolate

[0046] The extraction solvent (extractant) for extracting avenanthramide L is a mixture of water and an organic solvent. The organic solvent is preferably selected from the group consisting of foodstuffs, cosmetic or pharmaceutical preparations. It goes without saying that such solvents may be suitable for food, cosmetic or pharmaceutical products. It must be suitable and compatible with the preparation of the formulation.

[0047] In a more preferred variant, the extraction solvent comprises a mixture of water and alcohol or acetone. The alcohol is preferably methanol, ethanol, n-propanol, isopropanol. , n-butanol, isobutanol, t-butanol and mixtures thereof, i.e. The most preferred extraction solvents for the extraction step of the present invention are selected from the group consisting of The extractant is methanol, ethanol, n-propanol, isopropanol or acetone. tonnes, or any mixture of said solvents, each in admixture with water. The use of pure organic solvents is not favored by the simultaneous extraction of triglycerides.

[0048] The ratio of water to organic solvent in the extraction solvent, preferably the ratio of water to alcohol, The mixture ratio of acetone to water or the mixture ratio of acetone to water was determined based on the extraction solvent produced. , in the range of 10:90 to 90:10 (v / v), preferably 20:80 to 80:20 (v / v), and most preferably in the range of 30:70 to 70:30 (v / v). do.

[0049] Particularly preferred extraction solvents (extractants) are methanol / water (3:7), methanol / water (1 :1), methanol / water (7:3), ethanol / water (3:7), ethanol / water (1: 1), ethanol / water (1:4), ethanol / water (7:3), isopropanol / water ( 3:7), isopropanol / water (1:1), isopropanol / water (7:3), acetonitrile The mixtures used were acetone / water (3:7), acetone / water (1:1), and acetone / water (7:3).

[0050] To improve the extraction yield, the oat source is heated at 30 to 80°C, preferably 40 to 70°C. The extract is made from crushed oat kernels at a temperature in the range of 50-60°C. The extraction yield increases with increasing temperature between 40 and 70°C.

[0051] Apart from the avenanthramide compounds enriched, isolated, and purified from natural sources, Naturally occurring avenanthramides can be produced by organic synthesis. Methods for the synthesis of the compound are described, for example, in U.S. Pat. No. 6,096,770 and U.S. Pat. No. 6,127, ,392, Japanese Patent No. J60019754A and Hungarian Patent No. HU20099 An example is given in No. 6B.

[0052] The synthetic avenanthramide substances prepared above were the same as the corresponding avenanthramide substances isolated or extracted from oats. It is identical to the naturally occurring avenanthramide compound.

[0053] Formula 2 below: [ka] (wherein m=0, 1, 2 or 3; p=0, 1 or 2; n=0, 1 or 2, However, when n=1 or 2, p+m>0, R when n=1 or 2 1 and R 2 represents H for each pair. or together with other chemical bonds (e.g., as cinnamic acid derivatives), When m=1, 2, or 3, each X independently represents OH, Oalkyl, or Oacyl. Represents, When p=1 or 2, each Y independently represents OH, Oalkyl, or Oacyl. , If p+m>0, then at least one of X and Y is selected from the group consisting of OH and O acyl. provided that the compound is selected from the group consisting of R 3 is -H or alkyl (especially -CH3 or other alkyl groups having 2 to 30 carbon atoms). In this context, R 3 The corresponding pharmacologic approved (also -H for acceptable salts) and have important biological properties, hereinafter referred to as "similar compounds." In the compositions according to the present invention, the avenanthramide compound is also called an avenanthramide compound or an analog avenanthramide compound. Non-naturally occurring avenanthramide analogs are described, for example, in WO2004 / 047833A1 or or artificially produced by the organic synthesis method disclosed in WO2007 / 062957A1.

[0054] Particularly preferred compounds of formula 2 according to the invention are n=1 or 2 and p+m>0, and / or p+m>0, and at least one of X or Y or X and Y is OH and O The compound is selected from the group consisting of alkyl.

[0055] Particularly preferably, n=1 and p+m>2, provided that at least one of X and Y and the two of formula 2 are selected together from the group including OH and Oalkyl. A compound is used.

[0056] n=1 and m=1, 2 or 3, with the proviso that at least one X is OH and Oalkyl, and / or P=1 or 2, with the proviso that at least one Y is selected from the group consisting of OH and Oalkyl. It is also preferred to use a compound of formula 2

[0057] If n has the value 1, then R 1 and R 2 are each preferably H, with the proviso that R 1 and R 2 can also combine into other chemical bonds.

[0058] Formula 2 and WO2004 / 047833A1 or WO2007 / 062957A1 With respect to the definition of the specific avenanthramide compounds disclosed, the corresponding disclosures in the above documents are The disclosure is incorporated herein by reference.

[0059] The avenanthramide analog compound of formula 2 is preferably [ka] [ka] [ka] [ka] is selected from the group consisting of:

[0060] The above examples essentially relate to compounds of formula 2 where n=1.

[0061] However, the use of compounds of formula 2 where n=0 is also often preferred, in which case m+ p=0 or m+p>1 or 2, with the proviso that among the substituents X and Y, are selected from the group consisting of OH and Oalkyl. is preferred.

[0062] [ka] [ka] [ka] It is particularly preferred to use compounds of formula 2 (n=0) selected from the group comprising:

[0063] Particularly preferred are the compounds represented by these structural formulas, in which R 3 is always H be.

[0064] Instead of these preferred compounds, in each case, R 3 is CH3, or Use the corresponding compounds, which are linear or branched alkyl with 2 to 30 C atoms. It is also preferable to

[0065] From the above avenanthramide analogues, compound number 8 (dihydroavenanthramide D ) is particularly preferred.

[0066] In addition to the naturally occurring avenanthramides and non-naturally occurring avenanthramide analogs described above, , N-(4'-hydroxycinnamoyl)-3-hydroxyanthranilic acid (YAvn I) and N-(3'-4'-dihydroxycinnamoyl)-3-hydroxyanthranilic Novel avenanthramide analogues, including avenanthramide acid (YAvn II), are produced in recombinant yeast. These encode the main proteins involved in the biosynthesis of phenolic esters. Two plant genes (4cl-2 from tobacco and hc from artichoke) Engineering Saccharomyces cerevisiae strains using Notably, YAvn I and YAvn II were generated by They share structural similarities with Avn A and Avn C, respectively.

[0067] In the context of the present invention, naturally occurring avenanthramides obtained from natural sources or synthetically produced The modified avenanthramides are preferred and are used similarly.

[0068] The term "avenanthramide or an analog thereof" refers to the various isomers that exist. In particular, the naturally occurring trans-isomer and the cis-isomer, e.g., Photoisomerization induced by the photocatalytic reaction of cis-isomeric double bonds (formula 1 or 2 with n=1) or has one or two cis-isomeric double bonds (formula 1 or 2 with n=2) It is intended to include avenanthramides and the like.

[0069] In particular, within the context of the present invention, avenanthramides are represented by the general formula 1 and defined in Table 1. avenanthramide compounds, or any isomer or The avenanthramide analogues are represented by the general formula 2 and its definitions: or any one of its isomers as described above. do.

[0070] In a preferred variant of the invention according to the first aspect, the composition comprises avenanthramides A, B, Even more preferably avenans selected from the group consisting of C, G, H, K, L and R. At least one avenanthramide selected from the group consisting of avenanthramide A, B, C, or L. Includes do.

[0071] In another variation, the composition comprises avenanthramides A, B, C, G, H, K, L (non-choline abbreviation; CAS number 172549-38-1) (also called O or 2pd) and R Two, three, four or more avenges selected from the group consisting of A mixture of avenanthramides thus contains the following avenanthramides: It can contain any one of the combinations: A / B; A / C; A / G; A / H; A / K;A / L;A / R;B / C;B / G;B / H;B / K;B / L;B / R;C / G;C / H;C / K;C / L;C / R;G / H;G / K;G / L;G / R;H / K;H / L;H / R;K / L;K / R;and L / R;A / B / C;A / B / G;A / B / H;A / B / K;A / B / L;A / B / R;A / C / G;A / C / H;A / C / K;A / C / L;A / C / R;A / G / H;A / G / K;A / G / L;A / G / R;A / H / K;A / H / L; A / H / R;A / K / L;A / K / R;A / L / R;B / C / G;B / C / H;B / C / K, B / C / L;B / C / R;C / G / H;C / G / K,C / G / L;C / G / R,G / H / K;G / H / L;G / H / R;H / K / L, H / K / R;K / L / R;A / B / C / G;A / B / C / H;A / B / C / K;A / B / C / L;A / B / C / R;A / C / G / H;A / C / G / K;A / C / G / L;A / C / G / R;A / G / H / K;A / G / H / L;A / G / H / R;A / H / K / L;A / H / K / R;A / K / L / R;B / C / G / H;B / C / G / K;B / C / G / L;B / C / G / R;C / G / H / K;C / G / H / L; C / G / H / R; G / H / K / L; G / H / K / R and H / K / L / R.

[0072] However, the most preferred mixtures of avenanthramides are A / B, A / C, A / L, B / C, B / L and A / B / C, A / B / L or A / C / L.

[0073] In addition, the composition also contains avenanthramides A, B, C, G, H, K, L (non-Collins abbreviations). CAS number 172549-38-1) (also called O or 2pd) and other than R avenanthramides, such as avenanthramides D, E, FU, X, and Y (also called 2 ), AA, CC or OO or any of the remaining avenanthramide compounds in Table 1 may include.

[0074] In another variation, the composition of the present invention comprises avenanthramides A, B, C, G, H, K, L ( Non-Collins abbreviation; CAS number 172549-38-1) (also called O or 2pd) and R, i.e., one, two or more More avenanthramides can be synthesized by the avenanthramide analogue compound represented by formula 8 above. It contains the compound dihydroavenanthramide D in combination with the compound dihydroavenanthramide D. Therefore, it is a mixture of avenanthramides. may contain any one of the following: A / dihydroavenanthramide D; B / Dihydroavenanthramide D; C / Dihydroavenanthramide D; G / Dihydroavenanthramide Nanthramide D;H / dihydroavenanthramide D;K / dihydroavenanthramide D; L / dihydroavenanthramide D; or R / dihydroavenanthramide D; A / B / di Hydroavenanthramide D;A / C / Dihydroavenanthramide D;A / D / Dihydroavenanthramide Avenanthramide D;A / G / Dihydroavenanthramide D;A / H / Dihydroavenance A / K / Dihydroavenanthramide D; A / L / Dihydroavenanthramide D ;A / R / Dihydroavenanthramide D;B / C / Dihydroavenanthramide D;B / D / Dihydroavenanthramide D;B / G / Dihydroavenanthramide D;B / H / Dihydro Loavenanthramide D;B / K / Dihydroavenanthramide D;B / L / Dihydroavena Avenanthramide D;B / R / Dihydroavenanthramide D;C / D / Dihydroavenanthramide D;C / G / Dihydroavenanthramide D;C / H / Dihydroavenanthramide D;C / K / Dihydroavenanthramide D; C / L / Dihydroavenanthramide D; C / R / Di Hydroavenanthramide D;G / H / Dihydroavenanthramide D;G / K / Dihydroavenanthramide Avenanthramide D;G / L / Dihydroavenanthramide D;G / R / Dihydroavenance H / K / Dihydroavenanthramide D;H / L / Dihydroavenanthramide D ;H / R / Dihydroavenanthramide D;K / L / Dihydroavenanthramide D;K / R / dihydroavenanthramide D; or L / R / dihydroavenanthramide D combination. Even more preferably, A / dihydroavenanthramide D or avenanthramide L / dihydroavenanthramide D Hydroavenanthramide D may be included.

[0075] In addition to the above avenanthramide combinations, the composition also contains avenanthramides A, B, C, G, H, K, L (non-Collins abbreviations; CAS number 172549-38-1) (with O or 2pd) (also referred to as R) and one or more avenanthramides other than R, e.g., avenanthramide Mid D, E, FU, X, Y (also called 2), AA, CC or OO or as specified in Table 1 Any of the remaining avenanthramide compounds listed above and dihydroavenanthramide D The composition may further include a combination of

[0076] In yet another variation, the composition of the invention comprises dihydroavenanthramide D (2-{[ 3-(4-hydroxyphenyl)propanoyl]amino}benzoic acid;INCI name: Hydro Diphenylpropamidobenzoic acid (CAS 697235-49-7) or dihydroabe Nanthramide D and any of the compounds represented by general formula 1 and specified in Table 1 described above. or one or more different avenanthramides or compounds represented by general formula 2, as defined above; and combinations with identified avenanthramide analog compounds.

[0077] Naturally occurring avenanthramide compounds or non-naturally occurring avenanthramide analogue compounds Alternatively, the composition of the present invention comprises an oat extract containing at least one avenanthramide. Within the context of the present invention, the term "oat extract" generally refers to It is intended to include compounds or mixtures of compounds obtained from oats by extraction. do.

[0078] At least one avenanthramide or avenant as described above. Such extracts, including mixtures of amides, may be prepared by mixing water, alcohol, acetone or any combination thereof. Extraction using a mixture of (e.g., maceration, leaching, extraction by using a Soxhlet, microfiltration) or ultrasonic waves) or subcritical fluids using these solvents or mixtures of these These are preferably obtained by extraction with various solvent compositions, e.g. pure methanol. , ethanol, n-propanol, isopropanol, n-butanol, isobutanol , t-butanol and mixtures, i.e. combinations thereof, or in mixtures with water. Extraction is performed using a solvent, for example at room temperature or under controlled heating for different times. For example, the extraction procedure was accomplished using naked oat, 50% aqueous ethanol, etc. ng L. et al., Journal of Integrative Agriculture e, 2014, vol. 13, p. 1809]. Maliarova, M. et al., Journa l of the Brazilian Chemical Society, 2015 , Vol. 26(No. 11), pp. 2369-2378. The efficiency of methanol, ethanol and isopropanol was compared for the extraction of s. The optimal conditions for the highest yield of Avns were methanol concentration of 70%, extraction temperature of 55°C, and and extraction time 165 min.

[0079] The extract may be any of the Avena genus plants, particularly any oat species, fresh or dried, or any combination thereof. or parts thereof, such as crushed kernels, uncrushed kernels, husks, trichomes or From oat straw of the oat species Avena sativa or Avena nuda The starting product for the extraction is oat kernel residue obtained from oat oil production. There can be something.

[0080] In a preferred variant, the starting material for the oat extract is Avena sativa Seeds or Avena nuda seeds or oat straw, crushed or uncrushed It is a small grain.

[0081] Beneficially extract avenanthramide L and naturally occurring analogue avenanthramide compounds The extraction solvent (extractant) for the extraction is selected from the group consisting of a mixture of water and an organic solvent, the organic solvent being Preferably it is a solvent suitable for foodstuffs or cosmetic or pharmaceutical preparations. Such solvents are suitable and compatible for the preparation of food, cosmetic or pharmaceutical preparations. There must be sex.

[0082] In a more preferred variant, the extraction solvent comprises a mixture of water and alcohol or acetone. The alcohol is preferably methanol, ethanol, n-propanol, isopropanol. n-butanol, isobutanol, t-butanol and mixtures thereof The most preferred extraction solvent for the extraction step of the present invention is selected from the group consisting of (Extractant) is methanol, ethanol, n-propanol, isopropanol or acetone. or any mixture of said solvents, each in admixture with water. The use of pure organic solvents is not favored by the simultaneous extraction of triglycerides.

[0083] In the extraction solvent, water, organic solvent, preferably water, alcohol or water The mixing ratio of acetone to the resulting extraction solvent was 10:90 to 90: The ratio is in the range of 20:80 to 80:20 (v / v). and most preferably in the range of 30:70 to 70:30 (v / v).

[0084] Particularly preferred extraction solvents (extractants) are methanol / water (3:7), methanol / water (1 :1), methanol / water (7:3), ethanol / water (3:7), ethanol / water (1: 1), ethanol / water (1:4), ethanol / water (7:3), isopropanol / water ( 3:7), isopropanol / water (1:1), isopropanol / water (7:3), acetonitrile The mixtures used were acetone / water (3:7), acetone / water (1:1), and acetone / water (7:3).

[0085] From the extraction mixture (extractant), methanol / water (1:1), methanol / water (7:3 ), ethanol / water (1:1), ethanol / water (1:4), isopropanol / water (3 :7), isopropanol / water (1:1), isopropanol / water (7:3), acetone / water (3:7), acetone / water (1:1) and acetone / water (7:3) are particularly advantageous. This is because the extraction with these extractants resulted in high avenanthramide L content (see Table 10). These extractants result in extracts with The yield of venanthramide L is >150 ppm, more preferably >190 ppm. , most preferably >200 ppm.

[0086] To improve the extraction yield, the oat source is heated at 30 to 80°C, preferably 40 to 70°C. and more preferably at a temperature in the range of 50-60°C. The extraction yield for the crushed fermented soybean increases with increasing temperature between 40 and 70°C. Extraction from barley at temperatures between 50 and 60°C improves yield and avenanthramide content. It gave the best results in terms of content, especially avenanthramide L content, and therefore preferable.

[0087] Altering the composition of the solvent can affect the avenanthramide material to be extracted, and thus the composition. It is possible to change the extraction selectivity of a compound, thereby enhancing or decreasing its biological activity. Cut.

[0088] The oat extract of the composition according to the first aspect of the invention contains avenanthramides A, B, C, G, H, K, L (non-Collins abbreviations; CAS number 172549-38-1) (O or 2p At least one avenanthramide selected from the group consisting of: Includes.

[0089] In another variation, the oat extract contains avenanthramides A, B, C, G, H, K, L ( Non-Collins abbreviation; CAS number 172549-38-1) (also called O or 2pd) and R. A mixture of avenanthramides is therefore a mixture of avenanthramides. It can include any of the following combinations: A / B; A / C; A / G; A / H; A / K ;A / L;A / R;B / C;B / G;B / H;B / K;B / L;B / R;C / G;C / H ;C / K;C / L;C / R;G / H;G / K;G / L;G / R;H / K;H / L;H / R ;K / L;K / R;and L / R;A / B / C;A / B / G;A / B / H;A / B / K; A / B / L;A / B / R;A / C / G;A / C / H;A / C / K;A / C / L;A / C / R;A / G / H;A / G / K;A / G / L;A / G / R;A / H / K;A / H / L;A / H / R;A / K / L;A / K / R;A / L / R;B / C / G;B / C / H;B / C / K, B / C / L;B / C / R;C / G / H;C / G / K, C / G / L;C / G / R, G / H / K;G / H / L;G / H / R;H / K / L, H / K / R;K / L / R;A / B / C / G; A / B / C / H;A / B / C / K;A / B / C / L;A / B / C / R;A / C / G / H; A / C / G / K;A / C / G / L;A / C / G / R;A / G / H / K;A / G / H / L; A / G / H / R;A / H / K / L;A / H / K / R;A / K / L / R;B / C / G / H; B / C / G / K;B / C / G / L;B / C / G / R;C / G / H / K;C / G / H / L; C / G / H / R; G / H / K / L; G / H / K / R and H / K / L / R.

[0090] However, the most preferred mixtures of avenanthramides are A / B, A / C, A / L, B / C, B / L and A / B / C, A / B / L or A / C / L.

[0091] In addition, the oat extract also contains avenanthramide A, which occurs naturally in oats. , B, C, G, H, K, L (non-Collins abbreviations; CAS number 172549-38-1) (O or 2pd) and avenanthramides other than R, e.g. D, E, FU, X, Y (also called 2), AA, CC or OO or the rest of Table 1 or avenanthramide analogues according to formula 2 as specified above. The compound may include any one of the above.

[0092] In addition, the oat extract also contains at least one Avena species according to formula 2 specified above. The compounds may further include avenanthramide analog compounds, particularly dihydroavenanthramide D.

[0093] At least one avenanthramide or avenanthramine as described above. Analogues of avenanthramides or avenanthramides The mixture of amide analogue compounds is present in the composition or oat extract in an amount equivalent to the total weight of the composition. The amount of the amines may be present in a concentration or total amount of 0.0001 to 5.0% by weight based on the amount of the amines. In the present invention, the composition or oat extract contains at least one avenanthramide or avenanthramide. Nanthramide analogue compound or avenanthramide or avenanthramide analogue compound The mixture of the above substances is added at a concentration or total amount of 0.0005 to 2.0% by weight based on the total weight of the composition. and even more preferably, the concentration or total amount is from 0.001 to 1.0% by weight.

[0094] The second major component of the formulation according to the first aspect of the invention is at least one stabilizer. At least one stabilizer is selected from the group consisting of chelating agents, organic acids, antioxidants, and mixtures thereof. is selected from.

[0095] In the context of the present invention, the term "at least one stabilizer" means any one of The stabilizer may be a single stabilizer or more than one stabilizer, i.e., two or more stabilizers, i.e. combinations of stabilizers from one stabilizer category or different stabilizer categories. It is intended to include a combination of stabilizers from

[0096] In the context of the present invention, a stabilizer is a compound that prevents the degradation of the active ingredient of the composition, i.e., the avenanthramide. and thus inhibit or reduce the toxicity of other components of the composition or final product in which they are used. It is a chemical compound used to extend the shelf life of food without affecting its function.

[0097] Surprisingly, the present invention is directed to a compound selected from the group consisting of chelating agents, organic acids, antioxidants, and any mixture thereof. The combination of the avenanthramide with at least one stabilizer selected from the group consisting of or avenanthramide or more avenance It has been found to be beneficial in improving the stability of compositions containing the above-mentioned amides. The addition of one of the stabilizers significantly inhibits the decomposition of one of the avenanthramides. More surprisingly, the addition of one of the stabilizers according to the present invention reduces the most unstable of the avenanthramides. It is particularly effective in stabilizing the avenanthramide compound avenanthramide C, which is a known It has been found that.

[0098] Chelating agents are substances that form covalent coordination compounds with metal ions or metal atoms. These molecules or groups of atoms surround a central metal ion or atom, called As a Lewis acid, it donates its entire electron pair to a bond and thus acts as a catalyst Chelating agents are also called ligands, and complexes are called chelates. It is formed by:

[0099] In addition to chelating metals, chelating agents also act as antioxidant and preservative enhancers. Metal ions react with oxygen to form radicals and other reactions that can result in discoloration and odor. In peroxide formulations, metal ions may react with the peroxide to form peroxide species. This causes the decomposition of oxides and the generation of radicals. In addition, chelating agents enhance the activity of biocides. It has been found that this allows for significantly lower levels of biocide to be used.

[0100] By sequestering unwanted metal ions, chelating agents reduce the amount of water that causes hardness. Inhibits salt precipitation and protects against rancidity or color changes caused by heavy metals. Thus, the binding of metal atoms stabilizes the odor, structure and color of the finished preparation. This provides greater stability and longer shelf life to the composition or final formulation. Gives life.

[0101] In a preferred variant, the chelating agent used in the composition according to the first aspect of the invention is , EDTA or its sodium, calcium or magnesium salt, phytic acid, Tetrasodium glutamic acid diacetate, trisodium ethylenediamine disuccinate, citric acid Sodium, potassium citrate, sodium phytate, sodium gluconate, gluco Calcium Phosphate, Caprylhydroxamic Acid, Galactaric Acid, Galacturonic Acid, Metaphosphoric Acid Sodium, sodium polyitaconate, disodium etidronate and methylglycine trisodium diacetate.

[0102] Phytic acid is six times more abundant as a dihydrogen phosphate ester than inositol (specifically, the myo-isomer). (Inositol hexakisphosphate (IP6) or inositol Phytic acid and phytates are dietary minerals, including calcium, calcium phosphate ... It has a strong binding affinity for iron and zinc and inhibits their absorption.

[0103] As demonstrated in the examples below, the above identified chelating agents, EDTA or Its salts, trisodium ethylenediamine disuccinate or tetrasodium glutamate diacetate These are particularly preferred since they have particularly good decomposition inhibitory activity. The toxicity is such that, when used in accordance with the present invention, even low concentrations of these compounds can produce the desired results. EDTA, especially disodium EDTA, is the most effective single and is therefore the most preferred chelating agent as a stabilizer among chelating agents.

[0104] Further, the stabilizer is an organic acid having 2 to 10, preferably 3 to 8, carbon atoms. , can be characterized by a carboxyl (-COOH) functional group or gluconolactone Among organic acids, alpha hydroxy acids (AHAs) are preferred.

[0105] Alpha hydroxy acids (AHAs) are substituted with hydroxyl groups on adjacent carbon atoms. They are a class of chemical compounds consisting of carboxylic acids that occur naturally and can be synthesized AHAs are well known for their use in the cosmetic industry. In many cases, it helps reduce wrinkles, softening strong, defined lines and improving the overall appearance. Found in eye and skin feel improving products. They are also used as chemical peels. Sometimes AHAs are used for other purposes, e.g., to regulate pH, in cosmetics. Due to their acidity, alpha hydroxy acids are used in formulations with lower levels of This allows the product to have a preservative that is ideal for dry, sensitive or damaged skin. It is particularly beneficial for skin related

[0106] The alpha hydroxy acids according to the first aspect of the invention are gluconic acid, glyceric acid, glyceric acid, Cholic acid, isocitrate, lactic acid, malic acid, citric acid, mandelic acid, azelaic acid, anilic acid Acid, Ectoic Acid, Ferulic Acid, Folic Acid, Levulinic Acid, Niacin, Sebacic Acid, Salicylic Acid Acid, sorbic acid, tartaric acid, 2-hydroxybutyric acid (hydroxyaotanoic acid id), 2-hydroxydecanoic acid, mixtures of these or their salts and gluconolactone. tons.

[0107] In addition, the present invention also encompasses derivatives of AHA. Preferably, AHA is a derivative of these pharmaceutical Particularly preferred are monovalent or divalent salts and mixtures thereof. Among the salts, sodium salts, calcium salts, magnesium salts Or, ammonium salts are most preferred.

[0108] Throughout the present invention, the term "AHA" also refers to the stereoisomer, i.e., the R-enantiomer. This includes the S-enantiomer, the S-enantiomer, or the racemate.

[0109] Among the alpha hydroxy acids identified above, those as demonstrated in the following examples are Particularly preferred are citric acid, lactic acid, malic acid and tartaric acid. This is because it has a decomposition inhibitory activity. Good decomposition inhibitory activity means that, when used according to the present invention, This means that even low concentrations of these compounds produce the desired inhibition. Tartaric acid is the single most effective alpha hydroxy acid, and therefore, Among the alkoxy acids, the most preferred are as stabilizers.

[0110] Additionally, the stabilizer can be an antioxidant. Antioxidants are compounds that inhibit oxidation of oxygen, peroxides, and is a substance that inhibits oxidation or reactions driven by free radicals. The antioxidant according to one embodiment is 4-hydroxyacetophenone (p-hydroxyacetophenone). Non; INCI name Hydroxyacetophenone, CAS 99-93-4), Ascorbic Acid , 6-paradol, uric acid, butylhydroxytoluene luol)(BHT), butyl hydroxyanisole (BHA), ascorbyl palmitate Ascorbyl phosphate and its salts, Carnosine, Sodium Ascorbate, Rutini Tocopherol, tocopheryl acetate, ubiquinone, tropolone and allantoin The compound is selected from the group consisting of:

[0111] Among the antioxidants identified above, 4-hydroxybutyric acid is particularly preferred, as demonstrated by the following examples. Hydroxyacetophenone and ascorbic acid are particularly preferred because they are particularly The good decomposition inhibitory activity is that the use of the compound according to the present invention This means that even low concentrations of these compounds can produce the desired inhibition. Corbic acid is the single most effective antioxidant and therefore acts as a stabilizer among antioxidants. This is most preferable.

[0112] As demonstrated in the examples below, a stabilizer selected from the three groups described above The addition of one of the stabilizers described above increases the stability of the avenanthramide or one or more avenans. The stability of compositions containing sulamide is significantly enhanced. In particular, one of the stabilizers identified above is The addition of significantly inhibits the decomposition of avenanthramide C in the composition according to the present invention.

[0113] Among the stabilizers identified above, disodium EDTA, ascorbic acid, ethylenediaminetetraacetate, Most preferred are trisodium amine disuccinate, 6-paradol and phytic acid.

[0114] Surprisingly, the degradation of avenanthramides, and in particular the degradation of avenanthramide C, is prevented by the present invention. The composition comprises one stabilizer from each of two different categories of stabilizers described above. Stabilizing agents, i.e., chelating agents and alpha hydroxy acids, or chelating agents and antioxidants, If the stabilizer contains one each of alpha hydroxyl acid and antioxidant, The effect can be further reduced or inhibited by using the above-mentioned methods.

[0115] In another variation, the degradation of avenanthramides, particularly avenanthramide C, still occurs as follows: The compositions according to the invention may be prepared by mixing the three different categories of stabilizers described above. One stabilizer, i.e., chelating agent + alpha hydroxy acid + antioxidant stabilizer. When one stabilizer from each category is included, it further reduces or inhibits A preferred triple stabilizer combination is disodium EDTA + ascorbic acid. It is made up of carboxylic acid and citric acid.

[0116] Thus, a preferred variant of the composition according to the invention comprises two or even more It contains a combination of many stabilizers.

[0117] When stabilizers are used in such combinations, as demonstrated in the examples below, Inhibition of degradation can be significantly increased compared to the use of one single stabilizer.

[0118] From the above combinations, the following combinations of stabilizer compounds are preferred: Disodium EDTA + Ascorbic Acid; Disodium EDTA + Citric Acid; Disodium EDTA + 4-hydroxyacetophenone; Disodium EDTA + Lactic Acid; Disodium EDTA + Maleic Acid; Disodium EDTA + Tartaric Acid; Disodium EDTA + Phytic Acid; Ascorbic acid + disodium EDTA; Ascorbic acid + 4-hydroxyacetophenone; Ascorbic Acid + Tetrasodium Glutamic Diacetate; Phytic Acid + Tetrasodium Glutamic Acid Diacetate; Phytic acid + ascorbic acid; Phytic Acid + Disodium EDTA; Phytic acid + hydroxyacetophenone; Phytic acid + malic acid; 4-Hydroxyacetophenone + Disodium EDTA; 4-Hydroxyacetophenone + Ascorbic Acid; 4-Hydroxyacetophenone + Phytic Acid; 4-Hydroxyacetophenone + Tetrasodium Glutamic Acid Diacetate; 4-Hydroxyacetophenone + Trisodium Ethylenediaminedisuccinate; 6- Parador * + Disodium EDTA; 6- Parador * + Citric acid; 6- Parador * + Ascorbic acid; 6- Parador * + Tetrasodium glutamic acid diacetate; Disodium EDTA + Ascorbic Acid + Citric Acid.

[0119] In a preferred embodiment of the invention, there is even a synergistic effect for the following stabilizer combinations: Disodium EDTA + Ascorbic Acid; Disodium EDTA + 4-hydroxyacetone phenone; Disodium EDTA + Lactic Acid; Disodium EDTA + Maleic Acid; Disodium EDTA + Tartaric Acid; Disodium EDTA + Citric Acid Ascorbic acid + 4-hydroxyacetophenone; Ascorbic Acid + Tetrasodium Glutamic Diacetate; Ascorbic acid + phytic acid; Citric Acid + Tetrasodium Glutamate Diacetate Phytic Acid + Tetrasodium Glutamic Acid Diacetate; Phytic acid + ascorbic acid; Phytic Acid + Disodium EDTA; Phytic acid + hydroxyacetophenone; Phytic acid + malic acid; 4-Hydroxyacetophenone + Disodium EDTA; 4-Hydroxyacetophenone + Ascorbic Acid; 4-Hydroxyacetophenone + Phytic Acid; 4-Hydroxyacetophenone + Tetrasodium Glutamic Acid Diacetate; 4-Hydroxyacetophenone + trisodium ethylenediaminedisuccinate. 6- Parador * + Disodium EDTA; 6- Parador * + Citric acid; 6- Parador * + Ascorbic acid; 6- Parador * + Tetrasodium glutamic acid diacetate; Disodium EDTA + Ascorbic Acid + Citric Acid. *: 6-Paradol (INCI name: Hydroxymethoxyphenyldecanone; CAS 2711 3-22-0) is preferred over dipropylene glycol (DP 3-22-0) due to its better solubility in aqueous systems. Such blends of 6-paradol in DPG are preferably used as a solution in DPG. The trade name for this compound is SymDecanox DPG ex Symrise).

[0120] As will be seen from the examples below, the stabilizers are effective even at low concentrations.

[0121] The total amount of stabilizer present in the composition according to the invention is from 0.02 to 1000 mg / kg based on the total weight of the composition. In a preferred variant, the total concentration of stabilizers in the composition is is from 0.01 to 0.5% by weight, based on the total weight of the composition, and more preferably In general, the amount may be between 0.02 and 0.2% by weight based on the total weight of the composition.

[0122] Addition of one of the above stabilizers or combinations of stabilizers results in avenant lamination. The degradation of one of avenanthramides A, B, C, or L is significantly inhibited. The modulation of stabilization for C or L is 5% to 94.2% in total, preferably The range is 10% to 60%, and the modulation of stabilization, especially for avenanthramide C, is The concentration of the stabilizer is preferably 5% to 10%, depending on the concentration of the stabilizer, as demonstrated by the following application examples. 94.2%, preferably in the range of 10% to 6040%.

[0123] For example, the combination of disodium EDTA and citric acid is This resulted in 28.6% degradation of avenanthramide compared to 42.9% for the acid combination. When used at 0.1%, it is much more effective than EDTA alone at the same dose. It was more effective than thorium.

[0124] Furthermore, the addition of one of the above stabilizers or combinations of stabilizers can The degradation of nanthramide analogue compounds, especially dihydroavenanthramide D, is significantly inhibited.

[0125] In addition to the degradation stability described above, at least one stabilizing agent in the composition according to the first aspect of the present invention may be The agent reduces or even inhibits discoloration of the composition during storage, even at low concentrations. The following application examples demonstrate that existing stabilization with ascorbic acid is effective in preventing the formation of glycerol in the final product, especially in the This effect is of particular relevance since it causes discoloration in emulsion preparations. The composition according to the invention comprising an oat extract having s and a stabilizer does not contain a stabilizer. It was also observed to be more stable against light-induced degradation than the Avn-enriched product. This is particularly observable in the Avn C content.

[0126] As demonstrated in the examples below, a stabilizer selected from the three groups described above Adding one of the stabilizers to the avenanthramide or one or more avenanthramides The color stability of compositions containing nanthramide is significantly enhanced. In particular, the addition of one of the above stabilizers The addition of 1,2-dichlorophenyl ether significantly inhibits the decomposition of avenanthramide C in the composition according to the present invention. The enhanced stability is desirable even when these compounds are used in low concentrations according to the present invention. This means that inhibition of the

[0127] Regarding stabilizers, see above, these are also applicable to color stability. Among the stabilizers identified above, disodium EDTA, hydroxyacetophenone, Tetrasodium glutamic acid diacetate and 6-paradol are the most preferred monosodium glutamate with respect to color stability. It is a stabilizer.

[0128] The color stability of the composition according to the invention is also improved by the stability described above. One stabilizer from each of three different categories of stabilizers: chelating agents + alkalogen Alpha Hydroxy Acids, or Chelating Agents + Antioxidants, or Alpha Hydroxy Acids + Antioxidants When the composition contains one stabilizer from each category of stabilizer, the following examples are As demonstrated, further improvements can be made.

[0129] From the above combinations, the following stabilizers or combinations of stabilizer compounds are preferred in terms of color stability: New: Ascorbic acid; Citric acid; Lactic acid; Malic acid; Phytic acid; 4-Hydroxyacetophenone; SymDecanox DPG; Tetrasodium glutamic diacetate; Trisodium ethylenediamine disuccinate; Disodium EDTA + Ascorbic Acid; Disodium EDTA + Citric Acid; Disodium EDTA + 4-hydroxyacetone phenone; Disodium EDTA + Lactic Acid; Disodium EDTA + Maleic Acid; Disodium EDTA + Tartaric Acid; Disodium EDTA + Phytic Acid; Ascorbic acid + disodium EDTA; Ascorbic acid + 4-hydroxyacetophenone; Ascorbic Acid + Tetrasodium Glutamic Diacetate; Ascorbic Acid + Trisodium Ethylenediamine Disuccinate; Citric acid + tetrasodium glutamate diacetate; Phytic Acid + Tetrasodium Glutamic Acid Diacetate; Phytic Acid + Trisodium Glutamate Diacetate Phytic acid + ascorbic acid; Phytic Acid + Disodium EDTA; 4-Hydroxyacetophenone + Disodium EDTA; 4-Hydroxyacetophenone + Ascorbic Acid; 4-Hydroxyacetophenone + Trisodium Ethylenediaminedisuccinate; 6- Parador * + Disodium EDTA; 6- Parador * + Disodium EDTA; 6- Parador * + Citric acid; Disodium EDTA + Ascorbic Acid + Citric Acid.

[0130] In a preferred embodiment of the invention, a chelating agent is used in combination with an alpha hydroxy acid. When chelating agents are used in combination with antioxidants or when anti-oxidants are used in combination with anti-oxidants, Synergistic effects on color stability when sulfahydroxy acids are used in combination with antioxidants Thus, from the above combinations, the following combinations of stabilizer compounds are particularly preferable: Disodium EDTA + 4-hydroxyacetone phenone; Disodium EDTA + Lactic Acid; Disodium EDTA + Citric Acid Disodium EDTA + Maleic Acid; Disodium EDTA + Tartaric Acid; Ascorbic acid + disodium EDTA; Ascorbic acid + hydroxyacetophenone; Ascorbic Acid + Tetrasodium Glutamic Diacetate; Ascorbic acid + 6-paradol; Citric acid + tetrasodium glutamate diacetate; Phytic Acid + Disodium EDTA; Phytic Acid + Trisodium Ethylenediamine Disuccinate; Phytic Acid + Tetrasodium Glutamic Acid Diacetate; 4-Hydroxyacetophenone + Disodium EDTA; 4-Hydroxyacetophenone + Ascorbic Acid; 4-Hydroxyacetophenone + Trisodium Ethylenediaminedisuccinate; 6- Parador * + Disodium EDTA; 6- Parador * + Citric acid; Disodium EDTA + Ascorbic Acid + Citric Acid. *: 6-Paradol (INCI name: Hydroxymethoxyphenyldecanone; CAS 2711 3-22-0) is preferably dipropylene glycol due to its better solubility in aqueous systems. It is used as a solution in dichloromethane (DPG) (such a blend of 6-paradol in DPG) The trade name for this brand is SymDecanox DPG ex Symrise.

[0131] As will be seen from the examples below, the stabilizers can effectively stabilize color even at low concentrations. Cut.

[0132] Particularly preferred mixtures according to the invention are those in which the composition comprises, relative to the total weight of the composition: - 0.0001 to 5.0% by weight of at least one avenanthramide or its analogues or an oat extract containing at least one avenanthramide or analog thereof ; and - 0.02 to 0.5% by weight of at least one stabilizer, It is a mixture comprising or consisting of:

[0133] The compositions according to the invention, particularly those characterized as being preferred, have low avenin. The present invention has high color stability and avenanthramide decomposition. The stability and efficacy of the composition according to the present invention is surprisingly improved by the incorporation of one or more avenanthramides. It is superior to compositions containing only cosmetically or medicamentously active substances, i.e. Avenanthramides have some very interesting biological benefits, such as anti-inflammatory, antioxidant, and antioxidant properties. Exhibits antipruritic, anti-irritant and anti-atherogenic activity, thus allowing longer availability at therapeutically effective doses thus better reaching their intended targets.

[0134] The compositions according to the invention are also particularly effective and are effective in preventing any toxicological or dermatologically significant The composition does not contain any secondary components. Therefore, the composition is not useful in cosmetic or pharmaceutical preparations. can be used without further concern.

[0135] Stabilizers used in the compositions and final preparations in concentration ranges relevant for activity and administration are , in a concentration range relevant for activity and administration, - Toxicologically acceptable; - Well tolerated by the skin, - stable (especially in conventional formulations); - preferably odorless, and - It can be produced cheaply (i.e. using standard processes and / or Starting from standard precursors) Please keep this in mind.

[0136] The compositions according to the invention are therefore useful for skin protection and for the prevention and / or treatment of skin diseases. or is thus beneficial in treatment.

[0137] Thus, another aspect of the present invention relates to the use of a composition according to the first aspect of the present invention as a cosmetic agent. Use, especially in skin care, scalp care, hair care, nail care, or for skin conditions, Skin irritation, skin redness, wheals, pruritus (itching), skin aging, formation of wrinkles, loss of skin volume, loss of skin elasticity, pigmented spots, pigmentation abnormalities, or dry skin, i.e. Use as a cosmetic in the prevention and / or treatment of dry skin requiring skin moisturization. Regarding.

[0138] Another aspect of the invention relates to a composition according to the first aspect of the invention for use as a medicament. do.

[0139] Due to its excellent properties as described above, the preparation according to the first aspect of the present invention is effective in treating skin diseases or keratinocytes. Diseases, especially barrier-related inflammatory, immunoallergic, atherogenic, and dry skin disorders or prevention of skin or keratinopathy having a hyperproliferative component and / or in the treatment or prevention of cardiovascular disease, allergic reactions, coronary heart disease and / or In treatment, to reduce serum LDL cholesterol and lipid levels To reduce blood pressure, improve insulin sensitivity, and control blood sugar levels It is particularly useful to enable

[0140] Due to the specific antioxidant activity of avenanthramides, the present invention also aims to A composition according to the first aspect of the invention for use in the prevention and / or treatment of skin diseases. Also relates to.

[0141] Examples of such skin disorders include eczema, psoriasis, seborrhea, dermatitis, erythema, and pruritus (itching). , otitis, inflammation, irritation, fibrosis, lichen planus, pityriasis rosea, tinea versicolor, autoimmune blistering diseases , urticarial, angiodermal and allergic skin reactions and / or skin diseases associated with increased ROS generation. , atopic dermatitis, neurodermatitis, psoriasis, rosacea, acneiform eruptions, asteatosis and xerosis The compound is selected from the group consisting of:

[0142] In a particularly preferred variant of the invention, at least one avenanthramide or its analogues is The present invention relates to a method for treating a pulmonary artery disease comprising administering to a subject a patient a therapeutically effective amount of at least one avenanthramide or analog thereof. Compositions containing or consisting of oat extracts are useful for preventing and / or treating pruritus (itching). or is useful for providing benefit to treatment.

[0143] Chronic pruritus is a common symptom associated with a variety of skin conditions and systemic diseases and may Chronic pruritus is characterized by clinical symptoms (e.g., inflammatory / inflammation) and therefore no known underlying condition. Combined with the presence of inflammatory or normal / non-inflammatory skin and / or secondary scratch lesions and underlying causes (e.g., dermatologic, systemic, neurological, psychosomatic, mixed or They are classified according to their origin (uncertain origin).

[0144] Avenanthramide or its analogs or avenans for each of these purposes The use of oat extracts containing sulamide or its analogues provides a therapeutically effective amount of the active substance or The present invention relates to a method for imparting the therapeutic activity of each of the active substances by adding the composition. handle.

[0145] In the context of the present invention, an effective amount of a composition is defined as the amount of each active ingredient, i.e., avenin and providing a benefit, e.g., a reduction in symptoms associated with the disorder, disease, or condition being treated. When applied to a combination or composition, as in the present invention, , the term refers to the amount of combined active ingredients that provides a benefit.

[0146] Thus, the present invention relates to a method for treating a skin disease or keratinopathy, particularly a keratinopathy, in a subject in need thereof. Barrier-related inflammatory, immunoallergic, atherogenic, dry or excessive For preventing and / or treating skin or keratinopathy having a proliferative component The method of claim 1, further comprising administering to the subject at least one avenanthramide or analog thereof, an oat extract containing at least one avenanthramide or analog thereof; and Skin and keratinopathy, especially barrier-related inflammatory, immunoallergic, and atherogenic diseases Prevention of skin or keratinopathy with a mucous, dry or hyperproliferative component comprising or consisting of at least one stabilizer in an amount sufficient for the prevention and / or treatment of The method comprises administering a therapeutically effective amount of the composition.

[0147] Due to its remarkable action as described above, the composition according to the first aspect of the invention Advantageously suitable for the preparation of food, dietary supplement, cosmetic, pharmaceutical or veterinary preparations.

[0148] The compositions according to the invention may be used in combination with conventional food, dietary supplement, cosmetic, pharmaceutical or veterinary preparations. can be easily incorporated into

[0149] Thus, a further aspect of the present invention is a food product, a dietary supplement, comprising a composition according to the present invention. In a preferred embodiment of the invention, the composition comprises The functional food containing the above-mentioned ingredient may be used for skin care and / or to prevent the above-mentioned skin disorders or keratin disorders. It is provided as an active ingredient for the purpose of recovery.

[0150] In a preferred variant, the food, nutritional supplement, cosmetic, pharmaceutical or veterinary preparation is 0.0001 to 10% by weight, preferably 0.0005 to 5% by weight, based on the total weight of the product %, most preferably in an amount of 0.001 to 1% by weight of the composition or oat extract according to the present invention. These include products obtainable using the method according to the invention.

[0151] Within this context, it is also possible to combine the compositions according to the invention with other active compounds, e.g. other synergistically enhancing substances. For example, anti-inflammatory, antibacterial or antifungal substances, redness-relieving or itching-relieving effects. substances having therapeutic properties, analgesic substances, moisturizing and / or cooling agents and / or antioxidants , preservatives, (metal) chelating agents, penetration enhancers, and / or as cosmetic or pharmaceutical agents It is also possible, and in some cases advantageous, to combine the compound with a physiologically acceptable excipient. do.

[0152] Active agent refers to a substance or compound that confers a primary utility to a composition or formulation. Examples of such active substances include antioxidants, preservatives, (metal) chelating agents, penetration enhancers. Excipients are substances that are used to make cosmetics or pharmaceuticals as a result of processing or manufacturing. This refers to the inactive substances used to formulate a drug.

[0153] Skin conditions or diseases are often characterized by dry skin, scratchy skin, skin lesions or Furthermore, since inflammation is also involved, the cosmetic and / or pharmaceutical preparations are particularly advantageously suitable for moisturizing the skin. and / or moisture retaining substances, cooling agents, osmolytes, keratolytic substances, nutrients, anti- Anti-inflammatory, anti-bacterial or anti-fungal substances and / or redness-relieving or itching-relieving properties It contains analgesic and / or pain-relieving substances.

[0154] Itching occurs with particular intensity when the skin is dry. Skin moisturization and / or hydration Use of retention substances or conditioning agents in cosmetic and pharmaceutical preparations significantly reduces itching Thus, the cosmetic or pharmaceutical preparation according to the invention can also comprise one or Particularly advantageously in combination with a number of skin moisturizing and / or moisture retaining substances or conditioning agents. The cosmetic or pharmaceutical preparation according to the invention can therefore also advantageously comprise: The moisturizing and / or moisture retaining substances or regulators may include: sodium lactate Urea, urea derivatives, alcohols, glycerol, diols such as propylene glycol Recall, hexylene glycol, 1,2-pentanediol, 1,2-hexanediol 1,2-heptanediol, 1,2-octanediol, 1,2-nonanediol, 1,2-Decanediol or a mixture of said diols, in particular 1,2-hexanediol and and 1,2-octanediol, collagen, elastin or hyaluronic acid, Diacyl adipate, petrolatum, urocanic acid, lecithin, panthenol, phytanthate Lyol, lycopene, (pseudo)ceramide, glycosphingolipid, cholesterol, Fibrosterol, chitosan, chondroitin sulfate, lanolin, lanolin ester, amino Acids, alpha hydroxy acids (e.g., citric acid, lactic acid, malic acid) and their derivatives , monosaccharides, disaccharides and oligosaccharides, e.g., glucose, galactose, fructose, mannose, sugars, fructose and lactose, polysugars such as R-glucans, especially esters 1,3-1,4-β-glucan derived from barley, alpha-hydroxy fatty acids, triterpene acids, such as betulinic acid or ursolic acid, and algae extracts.

[0155] Depending on the substance, the concentration of the water retention regulator used is optimal for ready-to-use cosmetic or pharmaceutical applications. It is between 0.1 and 10% (m / m) based on the total weight of the final product, preferably between 0.5 and 5% (m / m). These data are especially relevant for the diols which are advantageously used. For example, hexylene glycol, 1,2-pentanediol, 1,2-hexanediol 1,2-octanediol and 1,2-decanediol, as well as 1,2-hexanediol. This applies to a mixture of 1,2-octanediol and 1,2-octanediol.

[0156] The use of cooling agents in cosmetic and pharmaceutical preparations can relieve itching. The preparations according to the invention are therefore particularly advantageously combined with one or more cooling agents. Particular cooling agents preferred for use within the framework of the present invention are listed below. A person skilled in the art would be able to add many other cooling agents to this list. The cooling agents listed may also be used in combination with one another: l-menthol, d-Menthol, racemic menthol, menthone glycerol acetal (trade name: Fre scolat(R) MGA), menthyl lactate (trade name: Frescolat(R) (TM)ML; menthyl lactate is preferably l-menthyl lactate, especially l-menthyl l-lactate substituted menthyl-3-carboxamides (e.g., menthyl-3-carboxylic acid N-ethylamide), 2-isopropyl-N-2,3-trimethylbutanamide, substituted silyl Cyclohexanecarboxamide, 3-menthoxypropane e)-1,2-diol, 2-hydroxyethyl menthyl carbonate, 2-hydroxy Propyl Menthyl Carbonate, N-Acetyl Glycine Menthyl Ester, Isopropyl Alcohol hydroxycarboxylic acid menthyl esters (e.g., menthyl 3-hydroxybutyrate g), monomenthyl succinate, 2-mercaptocyclodecanone, menthyl 2-pyrrolidine -5-one carboxylate, 2,3-dihydroxy-p-menthane, 3,3,5-tri Methylcyclohexanone glycerol ketal, 3-menthyl-3,6-di- and tri- Oxaalkanoates, 3-menthyl methoxyacetate and icilin.

[0157] Due to their specific synergistic effects, the preferred cooling agents are l-menthol, d-menthol, , racemic menthol, menthone glycerol acetal (trade name: Frescolat ( (registered trademark) MGA), menthyl lactate (preferably l-menthyl lactate, especially l-menthyl l -lactate (trade name: Frescolat® ML), substituted menthyl-3- Carboxamides (e.g., menthyl-3-carboxylic acid N-ethylamide), 2-isopropanol Pyr-N-2,3-trimethylbutanamide, Substituted cyclohexanecarboxamide, 3- Menthoxypropane-1,2-diol, 2-hydroxyethyl menthyl carbonate, 2-hydroxypropyl menthyl carbonate and isopulegol.

[0158] Particularly preferred cooling agents are l-menthol, racemic menthol, menthone glycerol Acetal (trade name: Frescolat® MGA), menthyl lactate (preferred or l-menthyl lactate, especially l-menthyl l-lactate (trade name: Frescolat (registered trademark) ML)), 3-menthoxypropane-1,2-diol, 2-hydroxyethyl 2-Hydroxypropylmenthyl carbonate and 2-hydroxypropylmenthyl carbonate.

[0159] Very particularly preferred cooling agents are l-menthol, menthone glycerol acetal ( Trade name: Frescolat® MGA) and menthyl lactate (preferably l- Menthyl lactate, especially l-menthyl l-lactate (trade name: Frescolat®) The mark is ML.

[0160] Depending on the substance, the concentration of the freshener used may vary depending on the composition of the ready-to-use cosmetic or pharmaceutical product. Preferably, the content is between 0.01 and 20% by weight, more preferably between 0.1 and 20% by weight, based on the total weight of the composition. 5% by weight.

[0161] The cosmetic or pharmaceutical preparations containing the composition according to the invention may also comprise one or more o It can also be used together with sumolite. Examples include sugar alcohols (myo-inositol, mannitol, sorbitol), quaternary aryl alcohols, amines, such as taurine, choline, betaine, betaine glycine, ectoine, diglycerine ol phosphate, phosphorylcholine or glycerophosphorylcholine, amino acids, e.g. For example, glutamine, glycine, alanine, glutamate, aspartate or proline. , phosphatidylcholine, phosphatidylinositol, inorganic phosphate, and combinations thereof Polymers of substances, such as proteins, peptides, polyamino acids and polyols All osmolytes simultaneously have a skin moisturizing effect.

[0162] Preferably, a keratolytic substance is also combined with the composition according to the invention or with the oat extract. Keratolytic compounds include a large group of alpha hydroxy acids. For example, salicylic acid is preferably used.

[0163] For example, for the topical cosmetic or pharmaceutical treatment of dry and / or itchy skin; In cosmetic or pharmaceutical preparations containing the composition according to the invention, a particularly high proportion of nutrients is The material is also particularly advantageous for reducing transepidermal water loss due to lipophilic components. In a preferred embodiment, the cosmetic or pharmaceutical preparation contains one or more nutritional ingredients. animal and / or vegetable fats and oils, e.g. olive oil, sunflower oil, refined oil, Soybean oil, palm oil, sesame oil, rapeseed oil, almond oil, borage oil, evening primrose oil , coconut oil, shea butter, jojoba oil, sperm whale oil, tallow, beef foot oil and lard, etc. and optionally other nutritious components, such as fats having 8 to 30 C atoms. As used herein, aliphatic alcohols may be saturated or unsaturated. The mixtures according to the invention are particularly Nutrients that can be preferably combined with the composition also include, in particular, ceramides, which are Here, we present the results of the study on N-acylsphingosine (Sphingosine), which significantly improves the water retention capacity of the stratum corneum. fatty acid amides of gosine) or synthetic analogues of such lipids (so-called pseudoceramides); Phospholipids, such as soy lecithin, egg lecithin and cephalin; and petrolatum, Paraffin oils and silicone oils are understood to mean the latter, among others, Alkyl- and alkylaryl siloxanes, for example, dimethylpolysiloxane and methylpolysiloxane. These include ethylphenyl polysiloxanes as well as their alkoxylated and quaternized derivatives.

[0164] Cosmetic or pharmaceutical preparations containing the composition according to the invention may also contain other anti-inflammatory active agents. The composition may contain an active compound or compounds that exhibit anti-redness and anti-itch activity. Intravenously, any anti-inflammatory active compound and relieve redness and itching, and can be used in cosmetics and / or Any active compound suitable or customary for use in treating skin conditions may be used. The active compounds used include anti-inflammatory agents and active agents that relieve redness and / or itching. The compound may be a steroidal anti-inflammatory agent of the corticosteroid class, e.g., hydrocortisone. , dexamethasone, dexamethasone phosphate, methylprednisolone or cortisol This list can be expanded by adding other steroidal anti-inflammatory drugs. Non-steroidal anti-inflammatory drugs, such as oxicams, e.g., piroxicam or tenoki Salicylates, e.g., Aspirin, Disalcid®, Solp rin® or fendosal; acetic acid derivatives, e.g., diclofenac, fen Clofenac, indomethacin, sulindac, tolmetin or clindanac; Fenam Acids, such as mefenamic acid, meclofenamic acid, flufenamic acid or niflumic acid; Pionic acid derivatives, such as ibuprofen, naproxen, benoxaprofen; or Pyrazoles, such as phenylbutazone, oxyphenylbutazone, febrazon or Azapropazone can also be used. Alternatively, natural anti-inflammatory substances as well as Substances that relieve redness and / or itching can also be used. Plant extracts, special high activity The use of highly purified plant extract fractions and extremely pure active substances isolated from the plant extracts. Chamomile, aloe vera, Commiphora species, Rubia species, willow , Willow herb, Ginger, Marigold, Arnica, Licorice seeds, Echinacea seeds, Extracts, fractions and active substances derived from Rubus species and pure substances, e.g., Bisa Borol, apigenin, apigenin-7-glucoside, gingerol, e.g., [6]- Gingerol, paradol, e.g., [6]-paradol, boswellic acid, phytosterol glycyrrhizin, glabridin or licocalcohol Histamine release inhibitor-containing preparations may also contain two or more anti-inflammatory agents. The composition may contain a mixture of active compounds.

[0165] Cosmetic or pharmaceutical preparations containing the compositions according to the invention may also contain active ingredients for preservation purposes. and may contain compounds suitable or customary for cosmetic and / or dermatological applications. Advantageously, for example, benzoic acid, its esters and salts; propionic acid and and its salts;Salicylic acid and its salts;2,4-hexanoic acid (sorbic acid) and its salts; Formaldehyde and paraformaldehyde; 2-hydroxybiphenyl ether and and its salts;2-Zinc sulfidopyridine N-oxide;Inorganic sulfites and bisulfites ;Sodium iodate;Chlorobutanol;4-hydroxybenzoic acid and its salts; Ester;Dehydroacetic acid;Formic acid;1,6-Bis(4-amidino-2-bromophenoxy) -n-Hexane and its salts;Sodium salt of ethylmercury-(II)-thiosalicylic acid; Phenylmercury and its salts;10-Undecylenic acid and its salts;5-Amino-1,3- Bis(2-ethylhexyl)-5-methylhexahydropyrimidine; 5-bromo-5-di 2-Bromo-2-nitro-1,3-propanediol;2, 4-Dichlorobenzyl alcohol;N-(4-chlorophenyl)-N'-(3,4-dichloro 4-Chloro-m-cresol;2,4,4'-trichloro-2' -Hydroxy-diphenyl ether;4-chloro-3,5-dimethylphenol;1,1 '-Methylene-bis(3-(1-hydroxymethyl-2,4-dioxyimidazolidine- 5-yl)urea;Poly(hexamethylene biguanide) hydrochloride;2-phenoxyethyle 1-(3-chloroallyl)-3,5,7-triaza;Hexamethylenetetramine;1-(3-chloroallyl)-3,5,7-triaza -1-Azoniaadamantane chloride;1-(4-chloro-phenoxy)-1(1H-isopropyl) 1,3-Bis(hydroxy)-3,3-dimethyl-2-butanone; Benzyl alcohol;O ctopirox®; 1,2-dibromo-2,4-dicyanobutane; 2,2' -Methylene-bis(6-bromo-4-chloro-phenol); Bromochlorophene; 5- Chloro-2-methyl-3(2H)-isothiazolinone and 2-methyl-3(2H)-isothiazolinone Mixtures of thiazolinone with magnesium chloride and magnesium nitrate; 2-benzyl-4- Chlorophenol; 2-chloroacetamide; Chlorhexidine; Chlorhexidine acetate ;Chlorhexidine gluconate;Chlorhexidine hydrochloride;1-phenoxy-propane-2 -ol; N-alkyl (C12-C22) trimethylammonium bromide and chlorine 4,4-Dimethyl-1,3-oxazolidine;N-Hydroxymethyl-N-(1, 3-Di(hydroxymethyl)-2,5-dioxoimidazolidin-4-yl)-N'-hydroxy Hydroxymethylurea; 1,6-bis(4-amidinophenoxy)-n-hexane and Its salts; glutaraldehyde 5-ethyl-1-aza-3,7-dioxabicyclo(3.3 .0) Octane; 3-(4-chlorophenoxy)-1,2-propanediol; High amine Benzyl ammonium chloride; alkyl (C8-C18) dimethyl benzyl ammonium chloride; alkyl (C8 ~C18) dimethylbenzylammonium bromide; alkyl(C8-C18) dimethylbenzylammonium bromide Benzylammonium saccharinate; Benzylhemiformal; 3-iodo-2-propionate Nylbutylcarbamate; or sodium ((hydroxymethyl)amino)acetate Any preservative selected from the group consisting of preservatives such as:

[0166] Other antibacterial or antifungal active substances may also be used in cosmetic or pharmaceutical preparations containing the composition according to the invention. They can be particularly advantageously used in pharmaceutical preparations, cosmetic and / or dermatological applications. Any antibacterial or antifungal active agent that is suitable or customary for the application can be used. In addition to the large group of conventional antibiotics, other products of interest here are those related to cosmetics. For example, in particular triclosan, climbazole, octoxyglycerin, Octopi rox® (1-hydroxy-4-methyl-6-(2,4,4-trimethylpentene) (ethyl)-2(1H)-pyridone 2-aminoethanol salt), chitosan, farnesol, glycerol monolaurate or combinations of the above substances, among others, It is used against body odor, foot odor or dandruff.

[0167] The cosmetic and / or pharmaceutical preparations according to the invention may also contain one or more analgesic substances. and any other suitable or customary cosmetic and / or pharmaceutical use. Any analgesic substances, such as alpha-bisabolol, azulene, guaiazulene, 18-β -Glycyrrhetinic acid, Allantoin, Aloe vera juice or gel, Hamameli Extract of Witch Hazel (Witch Hazel), Echinacea species, Centel la asiatica, chamomile, ginger extract, gingerol, Arnica monatana, Glycyrrhiza species, algae, seaweed and Calendula o fficinalis, and vegetable oils, e.g., sweet almond oil, baobab oil, o Leaf Oil, Panthenol, Laureth-9, Trideceth-9 and 4-t-Butylcyclohexylglycerin Xanol can be used.

[0168] In addition, cosmetic or pharmaceutical preparations may also contain antiperspirant activity to control body odor. It can be particularly advantageously used in combination with compounds (antiperspirants). As active compounds, in particular aluminum salts, such as aluminum chloride, chlorohydrate, nitrate, etc. However, the salts of zinc, magnesium or zirconium are not particularly limited. The use of aluminum compounds may also be advantageous. Aluminum salts and, to a somewhat lesser extent, However, the combination of aluminum / zirconium salts is used in cosmetic and dermatological antiperspirants. Therefore, partially neutralized aluminum hydroxide has been proven to be useful in It is also noteworthy that the cyclolides are better tolerated by the skin but are less effective. Materials other than aluminum salts can also be used, for example: Protein precipitating substances that cause the gland to seal on its surface, such as formaldehyde, among others. (b) ruthalaldehyde, natural and synthetic tanning agents and trichloroacetic acid; (c) local anesthetics A dilute solution of a drug, such as lidocaine, prilocaine, or a mixture of these, is administered to the peripheral nerves. Switching off the sympathetic nerve supply to the sweat glands by blocking the pathway; (c) X, A or Zeolites of the Y type, which also act as sweat secretion reducers and adsorbents of malodours; and (d) Botulinum toxin (a toxin from the bacterium Chlostridium botulinum) It is also used in hyperhidrosis (pathological increase in sweat secretion), and its action is related to the secretion of sweat. It is based on the irreversible blockade of the release of the neurotransmitter acetylcholine.

[0169] Combinations of (metal) chelating agents other than those mentioned above for use according to the invention It may also be advantageous in cosmetic or pharmaceutical preparations containing the composition according to the invention. and any metal cutting material suitable or customary for cosmetic and / or dermatological applications. Preferred (metal) chelating agents include α-hydroxy fatty acids. Fatty acids, phytic acid, lactoferrin, as well as humic acid, bile acids, bile extracts, bilirubin Examples of such compounds include erythropoietin, biliverdin or EGTA and their derivatives.

[0170] For use, the preparations containing the compositions according to the invention are prepared according to the usual methods for cosmetic and dermatological products. It is applied to the skin, scalp, hair and / or nails in a manner and in sufficient amount as is customary. Within this context, cosmetic products containing the mixture according to the invention and which additionally act as sunscreens are also suitable. The products and dermatological preparations offer certain advantages. Advantageously, these preparations comprise at least 1 UVA filter and / or at least 1 UVB filter and / or contains at least one inorganic pigment. Within this context, preparations of this type are, for example Preparations of, for example, solutions, water-in-oil (W / O) emulsions, oil-in-water (O / W) emulsions or muls Tiple emulsions, e.g., water-in-oil-in-water (W / O / W) emulsions, gels, hydrodispersions, It can take a variety of forms commonly used for solid sticks or aerosols. do.

[0171] Preparations containing the compositions according to the invention contain substances which absorb UV radiation in the UVB range. In an advantageous combination, the total amount of filter material, based on the dry weight of the preparation, is, for example, 0. 0.01 to 40% (m / m), preferably 0.1 to 10% (m / m), particularly 1.0 to 5.0 % (m / m) of a cosmetic preparation that provides hair and / or skin protection against the entire spectrum of ultraviolet light. These can also act as sunscreens for hair. If the preparations according to the invention contain UVB filter substances, these are oil-soluble. Advantageous oil-soluble UVB filters include: 3-benzylidene camphor derivatives, preferably 3-(4-methylbenzylidene) Camphor, 3-benzylidene camphor; 4-aminobenzoic acid derivatives, preferably 2- Ethylhexyl 4-(dimethylamino)benzoate, Amyl 4-(dimethylamino)benzoate Oleic acid salts; cinnamates, preferably 2-ethylhexyl 4-methoxycinnamate; Isopentyl 4-methoxycinnamate; Salicylic acid esters, preferably salicylic acid 2 -Ethylhexyl, 4-isopropylbenzyl salicylate, homomenthyl salicylate; Derivatives of benzophenone, preferably 2-hydroxy-4-methoxybenzophenone, 2- Hydroxy-4-methoxy-4'-methylbenzophenone, 2,2'-dihydroxy-4 -Methoxybenzophenone; benzalmalonic acid esters, preferably di(2-ethylhexyl 4-Methoxybenzalmalonate, 2,4,6-Trianilino-(p-Carbo-2 '-Ethyl-1'-hexyloxy)-1,3,5-triazine. Advantageous water-soluble UVB filter As a filter, salts of 2-phenylbenzimidazole-5-sulfonic acid, e.g. Sodium, potassium or triethanolammonium salts, as well as sulfonic acids and per se; sulfonic acid derivatives of benzophenone, preferably 2-hydroxy-4-methoxy Benzophenone-5-sulfonic acid and its salts; Sulfones of 3-benzylidenecamphor Acid derivatives, such as 4-(2-oxo-3-bornylidenemethyl)benzenesulfonic acid, 2-Methyl-5-(2-oxo-3-bornylidene-methyl)sulfonic acid and its derivatives Salts, and 1,4-di(2-oxo-10-sulfo-3-bornylidenemethyl)-benzene and its salts (the corresponding 10-sulfato compounds, e.g. the corresponding sodium, potassium ammonium and triethanolammonium salts), and benzene-1,4-di(2-oxo 3-bornylidenemethyl-10-sulfonic acid.

[0172] UVA filters, such as those commonly contained in cosmetic preparations, are used. These substances are preferably derivatives of dibenzoylmethane, especially 1-(4'-tert-butylphenyl)-3-(4'-methoxyphenyl)propane- 1,3-Dione and 1-phenyl-3-(4'-isopropylphenyl)propane-1 ,3-dione. The amounts used for the UVB combination can be similar. .

[0173] In cosmetic or pharmaceutical preparations, the compositions according to the invention can also advantageously contain, for example, Other auxiliaries or excipients normally used in such preparations, e.g., antioxidants, flavor oils, digestive agents, Foaming agents, coloring agents, pigments with coloring action, thickeners, surface-active substances, emulsifiers, plasticizing substances, moisturizing agents, Moisturizing and / or moisture-retaining substances, such as fats, oils, waxes or other conventional components of cosmetic preparations. Constituents such as alcohols, polyols, polymers, foam stabilizers, electrolytes, organic solvents or or silicone derivatives. Cosmetic and / or dermatological applications Any conceivable antioxidants, perfumes, antifoaming agents, colorants, which are suitable or customary in the Pigments with colouring action, thickeners, surface-active substances, emulsifiers, plasticising substances, wetting and / or or moisture-retaining substances, fats, oils, waxes, alcohols, polyols, polymers, foam stabilizers , electrolytes, organic solvents or silicone derivatives can be used here according to the invention. .

[0174] The high content of treatment substances is useful in the preparation of the present invention for topical, preventive or cosmetic treatment of the skin. It is generally advantageous in preparations containing the compositions according to the invention. The composition may comprise one or more animal and / or vegetable processed fats and oils, e.g., olive oil. Oil, sunflower oil, refined soybean oil, palm oil, sesame oil, rapeseed oil, almond oil, le Rijn oil, evening primrose oil, coconut oil, shea butter, jojoba oil, sperm whale oil, beef tallow, Cow foot oil and lard, and optionally other treated constituents, such as C8-C30 aliphatic As used herein, the fatty alcohol may be saturated or unsaturated and A linear or branched aliphatic alcohol, examples of which include decanol, decenol, octadecyl alcohol, nol, octenol, dodecanol, dodecenol, octadienol, decadienol Alcohol, dodecadienol, oleyl alcohol, ricinoleyl alcohol, erucic alcohol Alcohol, stearyl alcohol, isostearyl alcohol, cetyl alcohol, lauryl alcohol Alcohol, myristyl alcohol, arachidyl alcohol, capryl alcohol, caprylic Alcohol, linoleyl alcohol, linolenyl alcohol and behenyl alcohol The list may include, for example, the following alcohols: In some cases, this can be expanded to include other structurally and chemically related alcohols. The fatty alcohols are preferably derived from naturally occurring fatty acids, usually from the corresponding esters of the fatty acids. Prepared by reduction. Aliphatic acids formed by reduction from naturally occurring fats and fatty oils. Alcohol fractions, e.g. beef tallow, peanut oil, rapeseed oil, cottonseed oil, soybean oil, sunflower oil , palm kernel oil, linseed oil, corn oil, castor oil, rapeseed oil, sesame oil, cocoa butter And cocoa fat can also be used.

[0175] Treatment substances which may be preferably combined with the compositions according to the invention include also: Examples include: ceramides, what are thought to be N-acylsphingosines (sphingosines) fatty acid amides of vingosine) or synthetic analogues of such lipids (so-called pseudoceramides ), which significantly improve the water-retaining capacity of the stratum corneum; phospholipids, e.g. soybean residues tin, egg lecithin and cephalin; Vaseline, paraffin and silicone oil The latter are, inter alia, dialkyl- and alkylaryl-siloxanes, e.g., dimethylpolysiloxanes. Polysiloxanes and methylphenylpolysiloxanes, as well as their alkoxylated derivatives. and quaternized derivatives.

[0176] Hydrolyzed animal and / or vegetable proteins may also be included in the composition according to the invention. In this connection, particularly elastin, collagen, collagen fibres and collagen fibres can be advantageously added to the preparation. Lagen, keratin, milk protein, soy protein, oat protein, bean tan Protein, almond protein and wheat protein fraction or corresponding hydrolyzed protein These include proteins and their condensation products with fatty acids, as well as quaternized hydrolyzed proteins. Preferably, hydrolyzed vegetable proteins are used.

[0177] Cosmetic or dermatological preparations containing the compositions according to the invention are solutions or lotions. where R is an integer from 1 to 3, solvents that can be used include: water or aqueous solutions; fats Oils, fats, waxes and other natural and synthetic fatty bodies, preferably fatty acids and low carbon numbers Esters with alcohols having the formula: isopropanol, propylene glycol or The esters are either glycerol or fatty alcohols with low carbon number alkanoic acids. or fatty acid esters; alcohols, diols or polyols with low carbon numbers and and their ethers, preferably ethanol, isopropanol, propylene glycol , glycerol, ethylene glycol, ethylene glycol monoethyl or monobutyl ether, propylene glycol monomethyl, monoethyl or monobutyl ether, di Ethylene glycol monomethyl or monoethyl ether and similar products. In particular, mixtures of alcoholic solvents are used. In the case of alcoholic solvents, water is an additional constituent. can be done.

[0178] Cosmetic or pharmaceutical preparations containing a composition according to the invention also include those according to the first aspect of the invention. It may also contain antioxidants different from those of the composition according to the invention, and may be used in cosmetics and / or Any antioxidant suitable or conventional for dermatological applications may be used. In the 1990s, antioxidants were found in the amino acids (e.g., glycine, histidine, tyrosine, tryptophan, etc.) ) and derivatives thereof, imidazoles (e.g. urocanic acid) and derivatives thereof, Peptides, such as D,L-carnosine, D-carnosine, L-carnosine and the like Derivatives of carotenoids (e.g. anserine), carotenoids, carotenes (e.g. α-carotene, β-carotene) lycopene, lycopene) and their derivatives, lipoic acid and its derivatives (e.g. dihydrolipid thioglucose, propylthiouracil and other thiols (e.g., thiol Doxin, glutathione, cysteine, cystine, cystamine and their glycosyl , N-acetyl, methyl, ethyl, propyl, amyl, butyl and lauryl, palmitoyl yl, oleyl, gamma-linoleyl, cholesteryl and glyceryl esters) and Salts thereof, dilauryl thiodipropionate, distearyl thiodipropionate, thiodipropionate Pionic acids and their derivatives (esters, ethers, peptides, lipids, nucleotides, Nucleosides and salts) and sulfoximine compounds (e.g. buthionine sulfoximine Homocysteine ​​sulfoximine, buthionine sulfone, penta-, hexa-, hepta -Thionine sulfoximine) (these are tolerated at very low doses), and also (metals) Chelating agents, such as alpha-hydroxy fatty acids, palmitic acid, phytic acid, lactoferrin , α-hydroxy acids (e.g. citric acid, lactic acid, malic acid), humic acid, bile acids, bile extract substances, bilirubin, biliverdin, EDTA, EGTA and their derivatives, unsaturated fats acids and their derivatives (e.g., gamma-linolenic acid, linoleic acid, oleic acid), folic acid and and their derivatives, ubiquinone and ubiquinol and their derivatives, vitamin C and Its derivatives (e.g., ascorbyl palmitate, magnesium ascorbyl phosphate, scorbyl acetate), tocopherols and their derivatives (e.g., vitamin E acetate, acetate), vitamin A and its derivatives (e.g., vitamin A palmitate), and Coniferyl benzoate of benzoin resin, rutinic acid and its derivatives, ferulic acid (f errulic acid) and its derivatives, butylhydroxytoluene, butyl hyd Nordihydroguaiacinic acid, Nordihydroguaiaretic acid, Tri Hydroxybutyrophenone, uric acid and its derivatives, mannose and its derivatives, zinc and its derivatives (e.g., ZnO, ZnSO4), selenium and its derivatives (e.g., Se methionine), stilbene and their derivatives (e.g., stilbene oxide, t trans-stilbene oxide), as well as derivatives of the active compounds (e.g., salts, estilbene oxides, esters, ethers, sugars, nucleotides, nucleosides, peptides and lipids), e.g. It is selected from the group consisting of those which are suitable according to the invention.

[0179] Cosmetic or pharmaceutical preparations containing the compositions according to the invention also contain vitamins and vitamin These may also contain amine precursors, making them suitable or suitable for cosmetic and / or dermatological applications. Any vitamins and vitamin precursors that are conventional can be used. and vitamin precursors, e.g., tocopherols, vitamin A, nicotinic acid and nicotine Particular mention is made here of amides, other B-complex vitamins, especially biotin, and vitamin C. Other examples within this group which are preferably used include pantothenyl alco and its derivatives, in particular its esters and ethers, as well as cationically derived paraffins. Derivatives of pantothenyl alcohol, such as pantothenyl alcohol triacetate, Pantothenyl alcohol monoethyl ether and its monoacetate and also cathi and ionic pantothenyl alcohol derivatives.

[0180] Cosmetic or pharmaceutical preparations containing the composition according to the invention may also have an active ingredient having a whitening effect. and may contain hydroxylase compounds suitable for cosmetic and / or dermatological applications. Any conventional whitening active compound can be used in accordance with the present invention. Among the useful whitening active compounds are kojic acid, hydrochloric acid, which contains whitening stilbene derivatives. Quinone, Arbutin, Ascorbic Acid, Magnesium Ascorbyl Phosphate, Resorcinol Licorice root extract and its constituents glabridin or licochalcone A, or extracts from Rumex and Ramulus species, extracts from pine species (Pinus) or or extracts from Vitis species.

[0181] Cosmetic preparations containing the composition according to the invention also contain active agents having a skin tanning action. and may contain compounds suitable or customary for cosmetic and / or dermatological applications. Any skin tanning active compound that is conventionally used may be used. HA; 1,3-dihydroxy-2-propanone) can be mentioned here as an example. DHA may be provided in either monomeric or dimeric form, with the proportion of dimers being is predominant in crystalline form.

[0182] Cosmetic or pharmaceutical preparations containing the composition according to the invention may also contain monosaccharides, disaccharides and saccharide units. Oligosaccharides, such as glucose, galactose, fructose, mannose and lactose It may also contain cellulose.

[0183] Cosmetic or pharmaceutical preparations containing the composition according to the invention also contain plant extracts. These are usually prepared by extracting the whole plant, although in individual cases It may be prepared solely from the flowers and / or leaves, wood, bark or roots of the plant. Regarding plant extracts which can be used, in particular Leitfaden zur I nhaltsstoffdeklaration kosmetischer Mitt el(Guide to the Declaration of Constitution nts of Cosmetic Agents), Industrieverband Koerperpflegemittel und Waschmittel eV .(IKW)(Industrial Association for Toilet ries and Detergents, Frankfurt, 3rd edition, p. 44 See the extracts listed in the tables beginning with "Extracts of Natural Herbs and Herbs ... mamelis, algae, oak bark, willow herb, nettle, dead nettle, hops, duck Meal, yarrow, arnica, calendula, burdock root, horsetail, hawthorn, linden Blossom, cucumber, almond, pine needles, horse chestnut, sandalwood, juniper -, coconut, mango, apricot, orange, lemon, lime, grapefruit, linseed Goat, green tea, grapefruit seed, wheat, oats, barley, sage, thyme, basil , rosemary, birch, mallow, cardamom, willow bark, hawthorn, These include coltsfoot, velvet mallow, ginseng and ginger root. Particularly preferred extracts include aloe vera, chamomile, algae, rosemary, and calendula. tura, ginseng, cucumber, sage, nettle, linden blossom, arnica and Mixtures of two or more plant extracts may also be used. The extraction agent that can be used to prepare the plant extract is water, alkanol, ethyl alcohol ... Preferred alcohols in this context include: Lower alcohols, such as ethanol and isopropanol, but polyhydric alcohols, For example, ethylene glycol, propylene glycol and butylene glycol are also preferred. It is preferred, particularly both as the sole extractant and in a mixture with water. As disclosed herein, the plant extracts may be used in pure or diluted form.

[0184] Cosmetic or pharmaceutical preparations containing the composition according to the invention may also contain, in particular, crystalline or microcrystalline When crystalline solids, such as inorganic micropigments, are incorporated into the preparation according to the invention, anionic The composition may contain ionic, cationic, nonionic and / or amphoteric surfactants. Surfactants are amphiphilic substances that are capable of dissolving organic, non-polar substances in water. Surfactants are generally classified according to the nature and charge of the hydrophilic portion of the molecule. There are four groups: Here one can distinguish: anionic surfactants, cationic surfactants, amphoteric surfactants and and non-ionic surfactants.

[0185] Anionic surfactants usually contain carboxylate, sulfate or sulfonate groups. In aqueous solution, they form negatively charged organic imines in acidic or neutral media. Cationic surfactants are mostly based on the presence of a quaternary ammonium group. In aqueous solution, they form positively charged organic imines in acidic or neutral media. Amphoteric surfactants contain both anionic and cationic groups, but Depending on the pH value, they behave like anionic or cationic surfactants in aqueous solution. They carry a positive charge in a strongly acidic medium and a negative charge in an alkaline medium. In the pH range, by contrast, they are zwitterions. Polyether chains form non-ionic interfaces. Typical of active agents: Nonionic surfactants do not form ions in aqueous media.

[0186] Anionic surfactants which can be used advantageously include: acyla amino acids (and their salts), e.g., acyl glutamates, e.g., acyl glutamic acid Sodium, Di-TEA-Palmitoyl Aspartate and Caprylic / Capric Glycol sodium glutamate; acyl peptides, e.g. palmitoyl hydrolyzed milk protein, co Sodium Cocoyl Hydrolyzed Soy Protein and Sodium Cocoyl Hydrolyzed Collagen Calcium / potassium; Sarcosinates, e.g., myristoyl sarcosine, lauroyl sarcosine TEA, sodium lauroyl sarcosinate and sodium cocoyl sarcosinate; taurates, such as sodium lauroyl taurate and sodium methyl cocoyl taurate acyl lactylate, for example lauroyl lactylate and caproyl lactylate; Laninates; carboxylic acids and derivatives, e.g., lauric acid, aluminum stearate , magnesium alkanolates and zinc undecylates; ester carboxylic acids, e.g. Calcium Stearoyl Lactylate, Laureth-6 Citrate and PEG-4 Laureth Sodium myrocarboxylate; ether carboxylic acids, such as sodium laureth-13 carboxylate sodium and sodium PEG-6 cocamide carboxylate; phosphate esters and salts, e.g. For example, DEA-oleth-10 phosphate and dilaureth-4 phosphate; sulfonic acids and Salts, e.g., acyl isethionates, e.g., sodium / ammonium cocoyl isethionate alkyl aryl sulfonates; alkyl sulfonates, e.g., coco monoglycerides Sodium sulfonate, Sodium olefin (C12-14) sulfonate, Lauryl sulfonate Sodium fumarate and PEG-3 cocamide magnesium sulfate; sulfosuccinates, e.g. For example, dioctyl sodium sulfosuccinate, disodium laureth sulfosuccinate, Disodium Lauryl Sulfosuccinate and Undecylenamide MEA-2 sodium; and sulfates, e.g., alkyl ether sulfates, e.g., laureth sulfate. Sodium Laureth Sulfate, Ammonium Laureth Sulfate, Magnesium Laureth Sulfate, M Laureth Sulfate IPA, TIPA Laureth Sulfate, Sodium Myreth Sulfate and C12-13 Sodium Pareth Sulfate and alkyl sulfates, such as sodium lauryl sulfate, ammonium lauryl sulfate, Sodium and TEA Lauryl Sulfate.

[0187] Cationic surfactants which can be advantageously used include alkylamines, alkyl These include imidazoles, ethoxylated amines and quaternary surfactants.

[0188] Quaternary surfactants are surfactants that contain at least one alkyl group covalently bonded to four alkyl or aryl groups. Contains N atoms, which results in a positive charge regardless of the pH value. Alkyl betaines, Alkylamidopropyl betaine and alkylamidopropyl hydroxysulfane ( The cationic surfactant used is preferably Also preferred are the group of quaternary ammonium compounds, in particular benzyltrialkylammonium chlorides. ammonium or benzyltrialkylammonium bromide, for example benzyldimethylsulfonium chloride Tearyl ammonium, as well as alkyl trialkyl ammonium salts, such as cetearyl chloride. Cetyltrimethylammonium bromide or cetyltrimethylammonium bromide, alkyldichloride Methyl hydroxyethyl ammonium or alkyl dimethyl hydroxyethyl ammonium bromide ammonium, dialkyldimethylammonium chloride or dialkyldimethylammonium bromide ammonium, alkylamidoethyltrimethylammonium ether sulfate, alkylpi pyridinium salts, such as laurylpyridinium chloride or cetylpyridinium chloride, imidazolium chloride, Zoline derivatives and compounds of cationic nature, such as amine oxides, e.g. alkyl Selected from alkyl dimethylamine oxide or alkylaminoethyl dimethylamine oxide Cetyltrimethylammonium salts can be used with particular advantage. .

[0189] Amphoteric surfactants which can be advantageously used include acyl / dialkylethylene diamines. amines, such as sodium acylamphoacetate, disodium acylamphodipropionate, Disodium alkylamphodiacetate, sodium amphohydroxypropyl acylsulfonate um, disodium acylamphodiacetate and sodium acylamphopropionate;N -Alkylamino acids, e.g. aminopropyl alkylglutamides, alkylaminopropyl ionic acid, sodium alkylimidodipropionate and lauroamphocarboxyglyceryl Nate is one example.

[0190] Nonionic surfactants which can be advantageously used are: alcohols; alkanols Amides, e.g. cocamide MEA / DEA / MIPA, amine oxides, e.g. cocoa amidopropylamine oxide; ethylene oxide of carboxylic acids, glycerol, sorbitan or or other alcohols; ethers, e.g. Ethoxylated / propoxylated alcohols, ethoxylated / propoxylated esters, ethoxylated / propoxylated propoxylated glycerol esters, ethoxylated / propoxylated cholesterol, ethoxy Ethoxylated / Propoxylated Triglyceride Esters, Ethoxylated / Propoxylated Lanolin, Ethoxylated Polysiloxanes, propoxylated POE ethers and alkyl polyglyoxanes Glycosides, such as lauryl glucoside, decyl glucoside and coconut glucoside; glycerol esters and ethers; polyglycerol esters, diglycerol esters, Monoglycerol esters; methylglucose esters; esters of hydroxy acids. can be done.

[0191] Anionic and / or amphoteric surfactants and one or more nonionic surfactants The use of a surfactant in combination with the histamine release inhibitor according to the invention is also advantageous. In preparations containing the agent, at a concentration between 1 and 98% (m / m) based on the dry weight of the preparation It can exist.

[0192] Cosmetic or pharmaceutical preparations containing the composition according to the invention are preferably in a form suitable for topical application. For example, lotions, aqueous or aqueous-alcoholic gels, vesicle dispersions, or as simple or complex emulsions (O / W, W / O, O / W / O or W / O / W) Liquid, semi-liquid or solid, e.g. milk, cream, gel, cream-gel, It may also be formulated into a paste or stick, optionally as an aerosol. It may be packaged as a powder or may take the form of a mousse or spray. These compositions are prepared by conventional methods.

[0193] To prepare an emulsion, the oily phase can be advantageously selected from the following group of substances: Oils, mineral waxes; fatty oils, fats, waxes and other natural and synthetic fatty bodies, preferably Preferably, fatty acids and alcohols having low carbon numbers, such as isopropanol, propylene Esters with glycols or glycerol, or with fatty alcohols and low carbon numbers esters of alkanoic or fatty acids having the formula: alkyl benzoates; silicone oils; For example, dimethylpolysiloxane, diethylpolysiloxane, diphenylpolysiloxane and mixed forms thereof. Advantageously, saturated and / or non-saturated cyclic alkyl esters with a chain length of 3 to 30 C atoms. or unsaturated, branched and / or linear alkane carboxylic acids with a chain length of 3 to 30 C atoms Esters with saturated and / or unsaturated, branched and / or straight chain alcohols having aromatic carboxylic acids and saturated and / or unsaturated carboxylic acids with a chain length of 3 to 30 C atoms It is possible to use from the group of esters with cyclic, branched and / or linear alcohols. Preferred ester oils include isopropyl myristate, isopropyl palmitate, Isopropyl stearate, isopropyl oleate, n-butyl stearate, n-Hexyl oleate, n-decyl oleate, isooctyl stearate, stearyl Isononyl isononanoate, 2-ethylhexyl palmitate, 2-ethylhexyl isononate 2-Hexyl laurate, 2-Hexyldecyl stearate, 2-Octyl palmitate Decyl, Oleyl Oleate, Oleyl Erucate, Erucyl Oleate, Erucyl Erucate and synthetic, semi-synthetic and natural mixtures of such esters, e.g., jojoba oil. can be done.

[0194] The oil phase may also include branched and straight chain hydrocarbons and waxes, silicone oils, dialkyl ethers, The group includes esters, saturated or unsaturated, branched or straight chain alcohols, and fatty acid triglycerides. and in particular saturated and / or triglycerol esters of unsaturated, branched and / or linear alkane carboxylic acids The fatty acid triglycerides may be advantageously selected from synthetic, semi-synthetic and and natural oils, such as olive oil, sunflower oil, soybean oil, peanut oil, rapeseed oil, aloe vera oil, It may be advantageously selected from the group comprising mond oil, palm oil, coconut oil, palm kernel oil, etc. Any blend of such oil and wax components may also be used to advantage. In some cases, a wax, e.g., cetyl palmitate, is used as the only lipid component of the oil phase. It is also advantageous to use 2-ethylhexyl isostearate, octyl Dodecanol, isotridecyl isononanoate, isoeicosane, 2-coconut oil fatty acid ethylene C12-15 alkyl benzoate, caprylic / capric triglyceride and dicaprylyl ether. Mixture of alkyl and 2-ethylhexyl isostearate, C12-15 alkyl benzoate and isotridecyl isononanoate, and a mixture of C12-15 alkyl benzoate, 2 A mixture of ethylhexyl isostearate and isotridecyl isononanoate is particularly The hydrocarbons paraffin oil, squalane and squalene are also advantageously used. The oil phase may also advantageously contain or contain a cyclic or linear silicone oil. It can also consist entirely of one or more silicone oils, as well as other oil phase structures. Additional contents of the ingredient are preferably used. Cyclomethicone (e.g., decamethylcyclomethicone) Cloptasiloxane can be advantageously used as the silicone oil. Silicone oils such as undecamethylcyclotrisiloxane, polydimethylsiloxane, Poly(methylphenylsiloxane) and poly(methylphenylsiloxane) can also be used advantageously. methicone and isotridecyl isononanoate, and cyclomethicone and 2-ethylhexyl Mixtures of isostearate are also particularly advantageous.

[0195] As the aqueous phase of a preparation containing the composition according to the invention and provided in the form of an emulsion, and ethers thereof, preferably Ethanol, isopropanol, propylene glycol, glycerol, ethylene glycol ethylene glycol monoethyl or monobutyl ether, propylene glycol Monomethyl, monoethyl or monobutyl ether, diethylene glycol monomethyl or or monoethyl ether and similar products, as well as alcohols with low C numbers, e.g. For example, ethanol, isopropanol, 1,2-propanediol, glycerol and In particular, one or more thickening agents may be mentioned, such as silicon dioxide, aluminum silicate, etc. The group including polysaccharides and their derivatives, e.g., hyaluronic acid, xanthan gum , hydroxypropyl methylcellulose, particularly preferably from the group comprising polyacrylates, preferably Preferably, polyacrylates from the group containing the so-called Carbopol, e.g. Carbopol Models 980, 981, 1382, 2984, and 5984, each of which may be used by itself or in combination. In combination, these can be advantageously selected.

[0196] Cosmetic or pharmaceutical preparations containing the composition according to the invention and provided in the form of an emulsion may comprise One or more commonly used in the art for preparing cosmetic or pharmaceutical preparations It advantageously contains multiple emulsifiers.

[0197] Cosmetic or pharmaceutical preparations containing the composition according to the invention can also be used as cosmetics or A pharma- ceutically acceptable carrier, such as one of the following commonly used in the art: May include (but is not limited to): lactose, glucose, sucrose, sol Bitol, mannitol, starch, gum acacia, calcium phosphate, alginate, Gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose , Water, Syrup, Methylcellulose, Methyl Hydroxybenzoate, Propyl Hydroxide xybenzoate, talc, magnesium stearate, mineral oil, etc. Cosmetic or pharmaceutical The preparations may also contain, in addition to the above components, lubricants, wetting agents, sweeteners, flavoring agents, emulsifying agents, suspending agents, etc. Suitable pharma- ceutically acceptable carriers and preparations may include, for example, liquids, preservatives, etc. emington's Pharmaceutical Sciences (19th edition, This is described in detail in (1995).

[0198] Pharmaceutical preparations may be administered orally or parenterally.

[0199] The appropriate dose of the pharmaceutical preparation according to the present invention may be determined, for example, depending on the formulation method, age, weight, sex, etc. or disease-related condition, food, time and route of administration, rate of excretion and patient sensitivity. It can be formulated in a variety of ways depending on factors such as:

[0200] The pharmaceutical compositions according to the present invention can be prepared in unit dosage form and can be easily and conveniently administered by one of ordinary skill in the art to which the present invention pertains. The method can be easily carried out using pharma- ceutically acceptable carriers and / or excipients. The composition may be prepared by preparing a formulation.

[0201] Finally, the present invention provides a stabilizer for stabilizing avenanthramides or avenanthramides. In the case of the use of compositions containing avenanthramide, particularly avenanthramide C, the stabilizer is a chelating agent, Selected from the group consisting of organic acids having 10 carbon atoms, antioxidants, and mixtures thereof. will be done.

[0202] Although the present invention has been specifically shown and described with reference to preferred embodiments, and various changes in form and detail may be made without departing from the scope of the present invention. Moreover, the present invention is intended to cover all possible variations thereof. Unless specifically indicated otherwise, any combination of the above-described elements may be used. Includes.

[0203] In addition, while features or aspects of the invention are described in terms of Markush groups, those of skill in the art will appreciate that The present invention also relates to any individual member or subgroup of members of the Markush group. I am aware of what is stated here in this regard.

[0204] The present invention will now be described in detail with reference to the following examples, which are merely illustrative of the present invention. The invention is not limited by or to the following examples, which are merely illustrative of the invention. This is not to be the case. EXAMPLES

[0205] Example 1: Stabilization of Avn-containing DragoCalm® Extracts with Different Stabilizers Qualitative Testing

[0206] The following DragoCalm® extracts with different stabilizers are The oxidative stability of glycerol / water-based solutions was compared with that of stabilizer-free oat extract. Evaluated against a cellulose / water based solution.

[0207] DragCalm® stability testing was performed using Mikrolab's Oxipres device. The plates were preformed using a vice or in a Xenotest 440 instrument (60 W, 1294 kJ / m 2 The irradiation was carried out for 6 hours using a UV-cut filter (wavelength 300 to 400 nm).

[0208] The Oxipres device allows the determination of the oxidative resistance (shelf life) of oils. is a modified bomb method according to ASTM D941, and is based on oxidation with oxygen. The test operates at high pressure and temperature, through which the decomposition process is accelerated. The consumption of oxygen results in a pressure drop in the vessel. The reduction in pressure results in greater consumption of oxygen. This suggests a higher oxidation of the test products. The oils with higher unsaturation are least susceptible to autoxidation. Sunflower oil is an oil with highly unsaturated fatty acids and is therefore highly susceptible to oxidation. bring about.

[0209] The device can also simulate storage conditions for materials that do not have unsaturated fatty acids. This makes it possible.

[0210] The following test conditions are equivalent to storage of DragoCalm® for one month at 40°C. Therefore, due to more difficult conditions of temperature and pressure, for example, This is an accelerated stability test. DragoCalm® is a blend of: [Table 2]

[0211] Test procedure: Add the stabilizer to the DragoC solution with stirring at room temperature or, if necessary, at 40-50°C. Pre-dissolved in alm® (i.e. hydroxyacetophenone). The goCalm® sample (15 g) was placed in the reaction vessel and incubated with the Oxipres device. The specimens were exposed to 5 bar oxygen at 70°C for 24 hours using a gas pressure cooker.

[0212] The evaluation of the samples, i.e. the determination of the Avns content, was carried out by HPLC (Oxipre s comparison of pre- and post-treatment).

[0213] The content of avenanthramide C was determined by HPLC before and after Oxipres treatment. Ta.

[0214] Glycerol from the previously described DragoCalm® extracts with different stabilizers Color stability of glycerol / water-based solutions was compared with that of stabilizer-free oat extracts. The composition was evaluated against a cellulose / water based solution.

[0215] Additionally, the color of the DragoCalm® samples was measured using the L*a*b* system (Lic o690) before and after treatment with Oxipres. The values ​​describe the discoloration in the yellowish / reddish / brownish areas, and the Δb* values ​​are O The difference in color before and after treatment with Xipres is described. The higher the Δb* value, the The test solution has changed color more.

[0216] Table 2 below shows the results of avenanthramide C determination and color measurement after Oxipres treatment. Includes.

[0217] [Table 3-1] [Table 3-2] [Table 3-3]

[0218] The addition of a combination of acid, chelating agent and antioxidant improved the stability of avenanthramide C. It could be clearly observed that the improvement of the color of the samples was achieved by the addition of the fluoride. I was also able to show what I had not shown.

[0219] In addition, the stability of avenanthramide L was improved by the addition of a stabilizer. It was possible to do so.

[0220] The test procedures and evaluation of the samples were carried out in the same manner as described above. This was carried out against DoC.

[0221] [Table 4-1] [Table 4-2]

[0222] The addition of stabilizers improved the stability of avenanthramide L. The above results show that the stability can be further improved synergistically by the addition of the following stabilizer combinations: The results clearly show: 4-Hydroxyacetophenone + Ascorbic Acid Symdecanox DPG + Citric Acid Symdecanox DPG + Ascorbic Acid

[0223] In addition, improved stability of avenanthramide B was observed with the addition of stabilizers. Done.

[0224] The test procedures and evaluation of the samples were as described above for Avenanthramide C. was carried out in the same manner.

[0225] [Table 5-1] [Table 5-2]

[0226] The addition of stabilizers improved the stability of avenanthramide B. The above results show that the stability can even be improved synergistically by the addition of the following stabilizer combinations: clearly shows: Ascorbic Acid + Tetrasodium Glutamic Diacetate; Citric acid + tetrasodium glutamate diacetate; 4-Hydroxyacetophenone + Ascorbic Acid; Phytic Acid + Tetrasodium Glutamic Acid Diacetate; Phytic acid + ascorbic acid; Phytic acid + 4-hydroxyacetophenone; Tetrasodium glutamic diacetate + 4-hydroxyacetophenone; Disodium EDTA + Ascorbic Acid + Citric Acid.

[0227] Example 2: Stability test of dihydroavenanthramide D (before and after UV stress treatment)

[0228] Dihydroavenanthramide D is more stable than avenanthramide C, but U It is known that degradation occurs after treatment with V stress.

[0229] To evaluate the effect of different stabilizers on the stability of dihydroavenanthramide D, Prepare the following solutions (solutions A to D, solution A serves as a comparison) and perform a UV stress test for 6 Time processed.

[0230] The content of dihydroavenanthramide D was measured by HPLC before and after UV stress treatment. The Δb* values ​​were calculated based on the yellow / brownish color of the solution. A higher Δb* value indicates more discoloration.

[0231] [Table 6]

[0232] Dihydroavenanthramide D was converted to dipropylene glycol by heating the solution to 50°C. Pre-dissolve in ethanol. Add water and stir until a homogenous solution is achieved.

[0233] Test conditions UV stress test: Xenotest440 device 6 hours 1294kJ / m 2 Wavelength 300~400nm

[0234] [Table 7] Observe that the following combinations result in improved stability of dihydroavenanthramide D: Could be: Ascorbic Acid + Citric Acid SymDecanox DPG + Citric Acid SymDecanox DPG+Tetrasodium Glutamate Diacetate

[0235] The oat extract stabilized with at least one stabilizer is preferably the same as the oat extract without stabilizer. The results in Tables 2 to 4 and 6 clearly show that the extract is more stable against decomposition and discoloration. In addition, some stabilizer combinations have been shown to reduce the degradation of avenanthramide as well as the degradation of ember. Color stability of avenanthramide extracts and its analogues, especially dihydroavenanthramide D The results clearly show that there is even a synergistic effect on quality.

[0236] Example 3: Formulation examples

[0237] [Table 8-1] [Table 8-2]

[0238] [Table 9]

[0239] [Table 10]

[0240] [Table 11]

[0241] [Table 12]

[0242] The perfume oils PO1, PO2, PO3, PO4, or PO5 are prepared separately in each case. The preparations / formulations presented below were obtained.

[0243] Cosmetic preparations / formulations (amounts in % by weight of total preparations / formulations)

[0244]

Table 13

[0245]

Table 14

[0246]

Table 15-1

Table 15-2

[0247]

Table 16-1

Table 16-2

[0248]

Table 17

[0249]

Table 18

[0250]

Table 19

[0251]

Table 20-1

Table 20-2

[0252]

Table 21-1

Table 21-2

[0253]

Table 22-1

Table 22-2

[0254]

Table 23-1

Table 23-2

[0255]

Table 24-1

Table 24-2

[0256]

Table 25-1

Table 25-2

[0257]

Table 26

[0258]

Table 27

[0259]

Table 28

[0260]

Table 29

[0261]

Table 30

[0262]

Table 31

[0263]

Table 32

Table 33

[0264]

Table 34

[0265]

Table 35

[0266]

Table 36

[0267]

Table 37

[0268]

Table 38

[0269]

Table 39

[0270]

Table 40

[0271]

Table 41

[0272]

Table 42-1

Table 42-2

[0273]

Table 43

[0274]

Table 44

[0275]

Table 45

[0276]

Table 46

[0277]

Table 47

[0278]

Table 48

[0279]

Table 49

[0280]

Table 50

[0281]

Table 51

[0282]

Table 52

[0283]

Table 53-1

Table 53-2

Table 53-3

Table 53-4

Table 53-5

Table 53-6

Table 53-7

[0284]

Table 54

[0285]

Table 55

Claims

1. A composition comprising or consisting of at least one avenanthramide and at least one stabilizer, (a1) the at least one avenanthramide is avenanthramide C; (a2) the at least one stabilizer is selected from the group consisting of EDTA or a salt thereof, ascorbic acid, citric acid, lactic acid, 4-hydroxyacetophenone, malic acid, tartaric acid, tetrasodium glutamic acid diacetate, trisodium ethylenediamine disuccinate, phytic acid, 6-paradol, and mixtures thereof; or (b1) the at least one avenanthramide is avenanthramide L; (b2) the at least one stabilizer is selected from the group consisting of EDTA or a salt thereof, trisodium ethylenediaminedisuccinate, malic acid, tartaric acid, and mixtures thereof; or (c1) at least one avenanthramide is avenanthramide B; (a2) The composition, wherein the at least one stabilizer is selected from the group consisting of EDTA or a salt thereof, ascorbic acid, trisodium ethylenediamine disuccinate, malic acid, and mixtures thereof.

2. at least one avenanthramide selected from the group consisting of avenanthramides A, B, C, G, H, K, L and R and mixtures of these avenanthramides; at least two stabilizers selected from the group consisting of chelating agents, organic carboxylic acids having 2 to 10 carbon atoms, antioxidants, and mixtures thereof; A composition comprising or consisting of: the chelating agent is selected from the group consisting of EDTA or a salt thereof, phytic acid, tetrasodium glutamic acid diacetate, trisodium ethylenediamine disuccinate, and trisodium methylglycine diacetate; the organic carboxylic acid is selected from an alpha hydroxy acid selected from the group consisting of lactic acid, malic acid, citric acid and tartaric acid; A composition wherein the antioxidant is selected from the group consisting of 4-hydroxyacetophenone, ascorbic acid, 6-paradol, ascorbyl palmitate, ascorbyl phosphate and salts thereof, sodium ascorbate and allantoin.

3. dihydroavenanthramide D, an avenanthramide analog; at least two stabilizers selected from the group consisting of tetrasodium glutamic acid diacetate, citric acid, ascorbic acid, 6-paradol, ascorbyl palmitate, ascorbyl phosphate and salts thereof, and sodium ascorbate; A composition comprising or consisting of:

4. 3. The composition of claim 2, wherein the at least two stabilizers are a combination of a chelating agent and an organic carboxylic acid, a combination of a chelating agent and an antioxidant, or a combination of an organic carboxylic acid and an antioxidant, or a combination of a chelating agent, an organic carboxylic acid and an antioxidant.

5. At least two of the stabilizers are selected from the following stabilizer combinations: Disodium EDTA and ascorbic acid; Disodium EDTA and citric acid; Disodium EDTA and 4-hydroxyacetophenone; Disodium EDTA and lactic acid; Disodium EDTA and Malic Acid; Disodium EDTA and tartaric acid; Disodium EDTA and Phytic Acid; Ascorbic acid and 4-hydroxyacetophenone; Ascorbic acid and tetrasodium glutamic acid diacetate; Phytic acid and tetrasodium glutamic diacetate; Phytic acid and ascorbic acid; Phytic acid and malic acid; 4-hydroxyacetophenone and ascorbic acid; 4-hydroxyacetophenone and phytic acid; 4-Hydroxyacetophenone and tetrasodium glutamic acid diacetate; 4-Hydroxyacetophenone and trisodium ethylenediaminedisuccinate; 6-Paradol and disodium EDTA; 6- Paradol and citric acid; 6-Paradol and ascorbic acid; 6-Paradol and tetrasodium glutamic diacetate; Disodium EDTA, ascorbic acid and citric acid; The composition according to claim 2 or 4,

6. Based on the total weight of the composition, - 0.0001 to 5.0% by weight of at least one avenanthramide or its analogue dihydroavenanthramide D; and - 0.02 to 0.5% by weight of at least one or two stabilizers The composition of any one of claims 1 to 5, comprising:

7. 7. Use of a composition according to any one of claims 1 to 6 as a non-therapeutic cosmetic for skin protection and skin care, scalp protection and care, hair care, nail care or for moisturising the skin or in the prevention and / or treatment of skin ageing, wrinkle formation, loss of skin volume, loss of skin elasticity or pigmentation spots.

8. A composition according to any one of claims 1 to 6 for use as a medicament.

9. 9. A composition according to claim 8 for reducing serum LDL cholesterol and lipid levels, for reducing blood pressure, for improving insulin sensitivity and for allowing control of blood glucose levels, in the prevention and / or treatment of intolerable and sensitive skin, skin irritation, skin redness, skin conditions, dry skin, wheals, pruritus, pigmentation disorders, in the prevention and / or treatment of skin or keratinous disorders, skin or keratinous disorders having a barrier-related, inflammatory, immunoallergic, atherogenic, dry or hyperproliferative component, or in the prevention and / or treatment of skin disorders associated with increased ROS production, or in the prevention and / or treatment of cardiovascular diseases, allergic reactions, coronary heart disease.

10. 10. The composition of claim 9, wherein the skin or keratinous disease is selected from the group consisting of eczema, psoriasis, seborrhea, dermatitis, erythema, pruritus (itching), inflammation, irritation, fibrosis, lichen planus, pityriasis rosea, tinea versicolor, autoimmune blistering diseases, urticarial, angiodermal and allergic skin reactions, and wound healing, and / or the skin disease associated with increased ROS production is selected from the group consisting of atopic dermatitis, neurodermatitis, psoriasis, rosacea, acneiform rash, asteatosis and xerosis.

11. 7. Use of a composition according to any one of claims 1 to 6 for preparing a food, a dietary supplement, a cosmetic, a pharmaceutical or veterinary preparation, a dermatological or keratinological preparation.

12. 7. A food, a dietary supplement, a cosmetic, a pharmaceutical or a veterinary preparation, or a dermatological or keratinous preparation, comprising a composition according to any one of claims 1 to 6 in an amount of 0.0001 to 10% by weight, relative to the total weight of the preparation.

13. 13. Food, dietary supplement, cosmetic, pharmaceutical or veterinary preparation, or dermatological or keratinous preparation according to claim 12, further comprising one or more active substances selected from the group consisting of skin moisturizing and / or water retaining substances, cooling agents, osmolytes, keratin substances, nutritional substances, anti-inflammatory, antibacterial or antifungal substances, substances with redness-relieving or itching-relieving action, analgesic substances, and any mixtures thereof; and / or cosmetically or pharma- ceutically acceptable excipients selected from the group consisting of antioxidants, preservatives, (metal) chelating agents, penetration enhancers, surface-active substances, emulsifiers, perfume oils, defoamers, colorants, pigments with coloring action, thickeners, plasticizers, fats, oils, waxes or other conventional constituents of cosmetic compositions, such as alcohols, polyols, polymers, foam stabilizers, electrolytes, organic solvents or silicone derivatives, and any mixtures thereof.

14. 14. The food, dietary supplement, cosmetic, pharmaceutical or veterinary preparation, or dermatological or keratinological preparation according to claim 12 or 13, provided as a solution, tincture, lotion, emulsion, gel, cream, ointment, spray or shampoo.

15. Use of the stabilizer according to claim 1, The stabilizer (a2) according to claim 1 is used to stabilize avenanthramide C or a composition containing avenanthramide C to prevent decomposition or discoloration thereof, or The stabilizer (b2) according to claim 1 is used to stabilize avenanthramide L or a composition containing avenanthramide L to prevent decomposition or discoloration thereof; or 2. Use of the stabilizer (c2) according to claim 1 for stabilizing avenanthramide C or a composition containing avenanthramide C to prevent decomposition or discoloration thereof.

16. 1. The use of at least two stabilizers for stabilizing at least one avenanthramide or a composition comprising at least one avenanthramide to prevent decomposition or discoloration thereof, comprising: at least one avenanthramide is selected from the group consisting of avenanthramides A, B, C, G, H, K, L and R, and mixtures of these avenanthramides; the stabilizer is selected from the group consisting of a chelating agent, an organic carboxylic acid having 2 to 10 carbon atoms, an antioxidant, and mixtures thereof; the chelating agent is selected from the group consisting of EDTA or a salt thereof, phytic acid, tetrasodium glutamic acid diacetate, trisodium ethylenediamine disuccinate, and trisodium methylglycine diacetate; the organic carboxylic acid is selected from an alpha hydroxy acid selected from the group consisting of lactic acid, malic acid, citric acid and tartaric acid; The use, wherein the antioxidant is selected from the group consisting of 4-hydroxyacetophenone, ascorbic acid, 6-paradol, ascorbyl palmitate, ascorbyl phosphate and its salts, sodium ascorbate and allantoin.

17. 1. The use of at least two stabilizers for stabilizing the avenanthramide analog dihydroavenanthramide D or a composition containing the avenanthramide analog dihydroavenanthramide D to prevent decomposition or discoloration thereof, comprising: The use, wherein the stabilizer is selected from the group consisting of tetrasodium glutamic acid diacetate, citric acid, ascorbic acid, 6-paradol, ascorbyl palmitate, ascorbyl phosphate and its salts, and sodium ascorbate.

Images